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Abstract 
Dipeptidyl peptidase IV (DPPIV) – also known as CD26 – is a multifunctional 
transmembrane protease found on the surface of most human cells, and shows variable 
expression between different types of cancer. DPPIV activity may play a role in 
inhibiting cancer progression by interacting with components of the tumour 
microenvironment. DPPIV degrades several signalling molecules including the 
chemokine CXCL12. CXCL12 has been shown to facilitate tumour development when 
associating with its cell-surface receptor CXCR4. The cell-surface expressions of 
CXCR4 and DPPIV/CD26 exhibit an inverse relationship; an increase in DPPIV/CD26 is 
accompanied by a decrease in CXCR4, and vice versa. J-series prostaglandins (i.e. PGD2, 
PGJ2 and 15d-PGJ2)  have been shown to downregulate CXCR4 expression on colorectal 
carcinoma cells, which in turn may upregulate the expression and activity of 
DPPIV/CD26. Therefore, I investigated whether J-series prostaglandins altered 
DPPIV/CD26 expression and activity on colorectal cancer cells. Results showed that 
these prostaglandins did not upregulate DPPIV/CD26 mRNA expression, nor did they 
increase its whole-cell or cell-surface protein expression. J-series prostaglandins did 
increase the mean DPPIV/CD26 dipeptidase activity, however this increase was not 
statistically significant due to substantial inter-experimental variability. 15d-PGJ2 
treatment also significantly decreased the rate of cell migration on both CRC cells and 
normal fibroblasts. These findings suggest that J-series prostaglandins may promote 
DPPIV/CD26 specific activity in colorectal carcinoma. However, 15d-PGJ2 was found to 
be significantly unstable at high concentrations in serum-supplemented culture media and 
this instability in culture medium may explain the inconsistent cell response in vitro. 
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1. Introduction 
 
1.1 Colorectal Cancer 
1.1.1 Colorectal Cancer: A Perspective 
Colorectal cancer (CRC) is the third most common cancer and the second leading 
cause of cancer-related deaths worldwide (Siegel, DeSantis, & Jemal, 2014). Over 1 
million people are diagnosed with the disease each year (Siegel et al., 2014). Fortunately, 
early-stage CRC mortality rates have decreased due to significant improvements in 
diagnostic techniques, patient care, and therapeutic treatments (Arnold et al., 2017). 
However, most deaths from CRC occur in Stage IV when the cancer has spread to distant 
organs or metastasized. The 5-year survival rate of CRC patients dramatically drops from 
80-90% to 12.5% when the cancer metastasizes (Siegel et al., 2014). We must uncover 
the biological processes behind metastasis in order to develop new therapies and 
prevention strategies. In this project I have examined the relationship between three 
constituents of the tumour microenvironment (TME) – prostaglandins (PGs), CXCR4 and 
dipeptidyl peptidase IV/CD26 – that influence CRC progression and metastasis (Figure 
1.1). 
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Figure 1.1: Metastasis is influenced by the activities of prostaglandins (PGs), CXCR4 
and dipeptidyl peptidase IV (DPPIV) in the tumour microenvironment.  
 
1.1.2 Colorectal Risk Factors and Tumourigenesis  
Colorectal cancer can arise from lifestyle or hereditary factors. Most cases of 
CRC are sporadic; they occur spontaneously without genetic predisposition (Aaltonen et 
al., 1998). Risk factors for sporadic CRC are obesity, lack of physical activity, alcohol 
consumption, smoking, and excessive red meat intake (Itzkowitz & Yio, 2004; Johnson et 
al., 2013). Nevertheless, a small minority (2-5%) of CRC cases are hereditary (Jasperson, 
Tuohy, Neklason, & Burt, 2010). Individuals with hereditary CRC have inherited a 
condition that increases the risk of developing CRC such as familial adenomatous 
polyposis (FAP) and Lynch syndrome (Johnson et al., 2013). Individuals with FAP have 
a mutated adenomatous polyposis coli (APC) gene that causes tens to thousands of polyps 
to form in the colorectal mucosa, and these polyps can become cancerous (Half, 
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Bercovich, & Rozen, 2009). Individuals with Lynch syndrome have faulty DNA 
mismatch repair mechanisms, which increase the risk of developing cancerous mutations 
during DNA replication (Poulogiannis, Frayling, & Arends, 2010). Another more 
recently defined CRC subtype is colitis-associated colorectal cancer (CA-CRC). CA-
CRC develops from chronic gastrointestinal (GI) inflammatory conditions such as 
ulcerative colitis and Crohn’s disease (Munkholm, 2003).   
Cancer arises from the gradual accumulation of mutations in a somatic cell. 
Somatic mutations can occur at the single nucleotide level (e.g. point mutations) or at the 
chromosomal level (e.g. translocation, deletion, amplification and aneuploidy) (Loeb & 
Loeb, 2000). Mutations can result from a) physical DNA damage by environmental 
mutagens and free radicals, or b) errors in DNA replication by DNA polymerase (Loeb & 
Loeb, 2000). Mutations that activate proto-oncogenes (e.g. Ras genes HRas, KRas and 
NRas) and inhibit tumour suppressor genes (e.g. TP53 gene and APC gene) induce the 
malignant transformation of the cell (Downward, 2003; Muller & Vousden, 2013). The 
cell thereby acquires hallmark capabilities such as uncontrolled cell growth and division, 
and evasion of apoptosis or programmed cell death (Hanahan & Weinberg, 2000).   
Colorectal cancer occurs in the epithelia adjacent to the GI lumen. Accumulated 
genetic mutations result in uncontrolled proliferation of epithelial cells (Hanahan & 
Weinberg, 2000). Hyperproliferative cells form a circumferential tumour that invades the 
mucosa and submucosa of the GI tract (Gutman & Fidler, 1995). The growing tumour 
eventually protrudes into the lumen and expands through the successive layers of the 
colon – the muscularis propria and serosa (Zeng et al., 1992). A new capillary network 
forms around the tumour via angiogenesis – the formation of new blood vessels from 
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existing vasculature – providing the tumour with sufficient oxygen and nutrients to grow 
beyond 2 mm3 (Hillen & Griffioen, 2007). Tumour cells detach from the primary mass 
and enter the circulation by penetrating surrounding blood vessels (Carmeliet & Jain, 
2000). The few surviving malignant cells eventually exit the capillaries and enter the 
parenchyma of distant organs, where they further multiply and form a secondary tumour 
known as a metastasis (Fidler, 2002). CRC most often metastasizes to the liver since it 
directly connects to the GI tract via the hepatic portal vein (Figure 1.2) (Leporrier et al., 
2006).  
 
 
 
 
 
 
 
	   5 
 
	  
Figure 1.2: Colorectal cancer metastasis. 	  
Cancer cells detach from the colonic tumour and enter the circulation through 
surrounding capillaries. Circulating tumour cells can travel through the hepatic portal 
system to reach the liver, and then from the liver to the lung via the inferior vena cava 
and pulmonary circulation. Tumour cells exit the circulation and embed in the 
parenchyma of these distant organs where they hyperproliferate to form a secondary 
tumour. The liver is the most common site for CRC metastasis followed by the lung; 
however, a secondary tumour can also form in other organs. 
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1.1.3 Colorectal Carcinogenesis and Inflammation 
Chronic colorectal inflammation can lead to CA-CRC. Cancer often arises at the 
site of inflammation, and the risk of developing cancer increases with the duration and 
extent of inflammation (Rutter et al., 2004). During inflammation, signalling molecules 
recruit leukocytes from the venous system to destroy pathogenic substances, digest 
necrotic cells and repair damaged tissue (Ryan & Majno, 1977). Inflammation becomes 
chronic when it persists for several months to years without resolution (Shacter & 
Weitzman, 2002). Chronic inflammation involves repeated tissue damage and 
regeneration, coupled with the release of mutagenic free radicals and pro-tumorigenic 
signalling molecules, which creates an ideal environment for the onset of carcinogenesis 
(Franceschi & Campisi, 2014). Approximately 20% of patients with inflammatory bowel 
disease develop CA-CRC, and 50% of CA-CRC patients will die from the cancer 
(Ekbom, Helmick, Zack, & Adami, 1990a, 1990b; Lakatos & Lakatos, 2008). 
 1.1.4 Colorectal Carcinogenesis and Cyclooxygenase Enzymes 
Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) are two isozymes that 
likely promote CA-CRC development by sustaining inflammation in the tissue 
microenvironment. COX-1 and COX-2 catalyze the biosynthesis of signalling molecules 
called prostanoids including pro-inflammatory prostaglandins (Marnett, Rowlinson, 
Goodwin, Kalgutkar, & Lanzo, 1999). COX-1 is constitutively expressed, whereas COX-
2 expression is induced by inflammatory and growth stimuli (e.g. cytokines, tumour 
promoters and growth factors) (Vane, Bakhle, & Botting, 1998). COX-2 expression is 
significantly upregulated in patient colorectal tumours which is associated with worse 
patient prognosis through increased tumour size, invasiveness and metastasis (Chen et al., 
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2001; Eberhart & Dubois, 1995; Masunaga et al., 2000). Inhibiting COX-2 activity may 
significantly reduce the risk of CRC (Meade, Smith & DeWitt, 1993; Flossman & 
Rothwell, 2007; Rostom, Dube & Lewin, 2007). Nonsteroidal anti-inflammatory drugs 
(NSAIDs) (e.g. aspirin and ibuprofen) are over-the-counter COX inhibitors that have 
shown to hinder both the onset and progression of CRC (Meade, Smith, & DeWitt, 1993). 
Regular NSAID use over 10 to 15 years has shown to reduce the relative risk of CRC 
development by 40 to 50% (Flossmann & Rothwell, 2007; Rostom, Dube, & Lewin, 
2007). NSAID intake has also been associated with improved survival of patients with 
CRC, and reduced risk of cancer recurrence (Sandler et al., 2003). Targeting the COX 
pathway may prevent the onset of CRC, or help treat CRC after its onset.  
 
1.2 Prostaglandins 
1.2.1 Prostaglandin Structure  
Prostaglandins are small lipid molecules that mediate diverse physiological 
responses (Smith, 1989). They are a subclass of eicosanoids which derive from 20-carbon 
polyunsaturated fatty acids (Smith, 1989). Eicosanoids are synthesized by nucleated cells 
in most tissues and organs (Smith, 1989). Prostaglandins differ from other eicosanoids by 
their unique structure which has two side chains attached to a five-carbon ring at carbon-
8 and carbon-12 (Silver & Smith, 1975). Individual prostaglandins differ by the presence 
and positioning of double bonds, carbonyl groups and hydroxyl groups (Silver & Smith, 
1975). Each prostaglandin is named A through J, followed by a subscript denoting the 
number of double bonds within the side chains (Goldyne, 1975). The presence of  “α” or 
“β” after the subscript indicates the spatial orientation of the substitutions on the 5-carbon 
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ring (Goldyne, 1975). The structural differences between prostaglandins (Figure 1.3) 
distinguish their biological functions. 
 
  
 
Figure 1.3: The molecular structures of PGF2α, PGD2, PGJ2 and 15d-PGJ2 	  
(Adapted from Figarella et al., 2006).  
 
1.2.2 Prostaglandin Biosynthesis 
Prostaglandins derive from arachidonic acid (AA) – an omega-6 polyunsaturated 
fatty acid that is stored in glycophospholipids of the plasma membrane (Anggard & 
Samuelsson, 1965). Arachidonic acid is either directly obtained from dietary sources (e.g. 
meat, eggs, and fish) or synthesized from linoleic acid (Meyer et al., 2003). Prostaglandin 
synthesis commences when phospholipase A2 catalyzes the release of AA from 
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membrane glycerophospholipids (Figure 1.4) (T. Shimizu, Ohto, & Kita, 2006). COX-1 
and COX-2 add two oxygen molecules to AA to yield prostaglandin H2 (PGH2) (Marnett 
et al., 1999). Since PGH2 is highly unstable, it is immediately converted by inducible 
prostaglandin synthases and isomerases into bioactive prostaglandins (Vane et al., 1998). 
Inflammatory stimuli induce prostaglandin E synthase and prostaglandin F synthase to 
convert PGH2 into PGE2 and PGF2α, respectively (Herschman, 1996). PGH2 can also 
enter the J-series prostaglandin pathway; prostaglandin D synthase first converts PGH2 to 
PGD2 (Fitzpatrick & Wynalda, 1983). PGD2 is unstable in aqueous solution and 
spontaneously undergoes several dehydration reactions to form PGJ2, Δ12-PGJ2, and 15d-
PGJ2 (Fitzpatrick & Wynalda, 1983). These PGD2 derivatives are collectively known as 
the J-series prostaglandins. 
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Figure 1.4: Prostaglandin biosynthesis pathway.	  
Arachidonic acid is released from glycophospholipids of the plasma membrane via 
phospholipase A2 (PLA2). Arachidonic acid is converted to PGH2 by cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2). PGH2 is converted to either a) PGF2α by 
prostaglandin F synthase (PGFS), b) PGE2 by prostaglandin E synthase (PGES), or c) 
PGD2 by prostaglandin D synthase (PGDS). PGD2 is subsequently converted to PGJ2, 
which is then transformed to Δ12-PGJ2 and then 15d-PGJ2 (Adapted from Scher & 
Pillinger, 2004). 
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1.2.3 Prostaglandin Activity 
 Prostaglandins are called “autocoids” or “local hormones” because they exhibit 
autocrine or paracrine signalling, respectively (Shimizu & Nakamure, 1985). Unlike 
regular hormones, prostaglandins do not exhibit endocrine signalling; their short half-
lives render them biologically inactive in circulation (Folco & Murphy, 2006; Funk, 
2001). Prostaglandins are not usually stored in cells but are rather synthesized and 
secreted within 5 to 60 seconds of extracellular stimulation (Athari, Hanecke, & 
Jungermann, 1994; Camacho, Lopez-Belmonte, & Vila, 1998). Prostaglandins exit the 
cell by passive diffusion or through the multidrug resistance protein MRP4 transporter 
(Reid et al., 2003). Prostaglandins then activate specific G protein-coupled receptors 
(GPCRs) on the cell surface (Williams & Higgs, 1988). PGD2, PGE2, PGF2α and PGI2 
preferentially bind to DP, EP, FP, and IP receptors, respectively (Table 1.1) (Williams & 
Higgs, 1988). The J-series prostaglandins PGJ2, Δ12-PGJ2 and 15d-PGJ2 bind to DP2 
receptors with high affinity (Monneret, Li, Vasilescu, Rokach, & Powell, 2002). 15d-
PGJ2 also activates the intranuclear receptor peroxisome proliferator-activated receptor-
gamma (PPARγ) in addition to DP2 (Forman et al., 1995). Prostaglandins are catabolized 
by 15-hydroxyprostaglandin dehydrogenase which oxidizes the hydroxyl group on 
carbon-15 (Ensor & Tai, 1995). 
 Prostaglandins modulate a broad range of homeostatic and immunologic 
functions. They primarily regulate inflammation, blood pressure and platelet aggregation 
amongst other physiological activities (Table 1.1). Several prostaglandins can also alter 
the motility and absorption of the GI tract – namely PGE2 and PGF2α, which are the most 
abundant prostaglandins in the human colon (Bennett, Hensby, Sanger, & Stamford, 
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1981; Boughton-Smith, Hawkey, & Whittle, 1983; Matuchansky & Bernier, 1973; 
Milton-Thompson, Cummings, Newman, Billings, & Misiewicz, 1975). Depending on 
the type of prostaglandin they can either promote or inhibit a particular response. For 
example, PGE2 and PGD2 promote inflammatory responses, whereas 15d-PGJ2 is anti-
inflammatory (Ricciotti & FitzGerald, 2011; Rossi et al., 2000). 
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Prostaglandin Receptor(s) Main Functions 
PGD2 
DP1 
DP2 
Promotes sleep 
Promotes allergic responses (i.e. sneezing, 
bronchoconstriction) 
Promotes allergic inflammation (i.e. airway 
hyperreactivity, mucus production) 
Suppresses other types of inflammation (i.e. 
inhibits production of some immune cells and 
cytokines) 
PGE2 
EP1 
EP2 
EP3 
EP4 
Promotes inflammation (i.e. inducing pain, 
heat and fever) 
Induces vasodilation 
Inhibits PGD2-induced allergic responses 
PGF2α FP 
Generates uterine contractions & parturition 
Promotes acute inflammation 
Promotes renal function  
Induces vasoconstriction 
15d-PGJ2 
DP1 
DP2 
PPARγ 
Promotes anti-inflammatory responses 
Promotes adipocyte differentiation 
 
PGI2 IP 
Inhibits platelet aggregation 
Induces vasodilation 
Inhibits allergic inflammation 
Promotes embryo implantation 
Table 1.1: The receptors and functions of major prostaglandins. 
 
 (Ricciotti & FitzGerald, 2011; Rossi et al., 2000).  
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1.2.4 Prostaglandins in Cancer 
Prostaglandins can either inhibit or promote cancer progression depending on the 
molecule. PGE2 is upregulated in many different cancers, and has shown pro-tumorigenic 
effects in numerous in vitro and in vivo studies (Pugh & Thomas, 1994). For example, 
treating Caco-2 CRC cells with PGE2 has increased their survival by inhibiting apoptosis 
(Leone et al., 2007). Wang et al. (2004) also showed that PGE2 treatment promoted the 
survival of CRC cells, and increased intestinal polyp formation in Apcmin mice (i.e. mice 
with a mutated APC gene). Blocking PGE2 receptors EP3 and EP4 has reduced the 
number and size of intestinal polyps in APC knockout mice (Sonoshita et al., 2001). 
PGE2 may also facilitate metastasis by stimulating angiogenesis and suppressing 
immunosurveillance in the tumour microenvironment (Leahy, Koki, & Masferrer, 2000; 
Namkoong et al., 2005; Pai et al., 2001; Y. Sakai, Fujita, Sakai, & Mizuno, 2001).  
It has been suggested that COX inhibitors (e.g. NSAIDs) may prevent the onset 
and progression of CRC by inhibiting PGE2 production (Ghosh, Chaki, Mandal, & 
Mandal, 2010). However, other COX-derived prostaglandins can actually exert 
anticancer effects – particularly those synthesized through the J-series pathway. Yoshida 
et al. (1998) found that PGD2 treatment inhibited the proliferation of multiple CRC cell 
lines. The authors also measured the level of PGD2 in human patients’ resected colon 
tumours and found it to be negatively correlated with the incidence of liver metastasis. 
PGD2 metabolites have also shown anticancer activity in vitro, primarily by inhibiting 
cell growth and inducing apoptosis (Kim et al., 1993; Narumiya & Fukushima, 1985; 
Clay et al., 1999). Δ12-PGJ2 treatment has inhibited the growth of leukemia cells and 
caused them to undergo apoptosis in a dose-dependent manner (Kim et al., 1993; 
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Narumiya & Fukushima, 1985). Narumiya and Fukushima (1985) also found that Δ12-
PGJ2 was more potent than PGD2 in inhibiting cell growth, and suggested that the effects 
of PGD2 was actually exerted by the presence of Δ12-PGJ2, since PGD2 is rapidly 
converted to Δ12-PGJ2 in culture media. Furthermore, Δ12-PGJ2 and 15d-PGJ2 treatments 
have shown to induce apoptosis in breast cancer cells (Clay et al., 1999). 15d-PGJ2 has 
also caused apoptosis in gastric, pancreatic, lung and colorectal cancer cells, as well as 
leukemia cells (Chen, Zhong, Qin, Bing, & He, 2003; Hashimoto, Farrow, & Evers, 
2004; Shin et al., 2009).  
15d-PGJ2 may also interfere with angiogenesis. In one study by Xin, Yang, 
Kowalski & Gerritsen (1999), 15d-PGJ2 treatment showed to inhibit a) the tubular 
organization of human umbilical endothelial cells (HUVECs) in three-dimensional 
collagen gels, and b) vascular formation in the rat cornea (Xin, Yang, Kowalski & 
Gerritsen, 1999). 15d-PGJ2 treatment greatly reduced the area of new blood vessels that 
had resulted from exposure to the angiogenic protein vascular endothelial growth factor 
(VEGF) (Xin, Yang, Kowalski, & Gerritsen, 1999). Furthermore, 15d-PGJ2 has 
suppressed pancreatic xenograft tumour growth in nude mice by reducing the expression 
of VEGF, thereby hindering angiogenesis (Dong, Wang & Wu, 2009). 
1.2.5 15d-PGJ2 and Peroxisome Proliferator-Activated Receptor Gamma 
15d-PGJ2 may exert its anticancer effects through PPARγ. PPARγ is a 
transcription factor that is mainly expressed in adipocytes and colorectal epithelial cells 
(Fajas et al., 1997). It regulates the expression of numerous genes including those that 
code for proteins involved in cell differentiation, proliferation, apoptosis and migration as 
well as angiogenesis (Hsu & Chi, 2014; Lea, Sura, & Desbordes, 2004; Sarraf et al., 
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1998). 15d-PGJ2 is a natural ligand for PPARγ, whereas thiazolinediones (TZDs) (which 
are used to treat type II diabetes) are synthetic PPARγ ligands (Forman et al., 1995).   
PPARγ activation commences when 15d-PGJ2 binds to inactive PPARγ in the 
cytoplasm (Scher & Pillinger, 2005). PPARγ then dissociates from a co-repressor protein 
and the 15d-PGJ2/PPARγ complex translocates to the nucleus (Scher & Pillinger, 2005). 
The complex forms a heterodimer with the nuclear retinoid X receptor (RXR), which 
then binds to PPAR-response elements (PPRE) (Scher & Pillinger, 2005). PPREs are 
short DNA segments within the promoter region of a gene that bind peroxisome-
proliferator receptors (PPARs) (Abott, 2009). PPARγ thereby regulates the expression of 
genes that contain certain PPREs such as those that regulate apoptosis, cell growth, 
migration and angiogenesis (Hsu & Chi, 2014).  
 
1.3 The CXCL12/CXCR4 Axis 
Chemokines are small (8-10 kiloDalton) cytokines that induce chemotaxis in 
nearby cells (Luster, 1998). Chemotaxis is the directional movement of a cell in response 
to a chemokine concentration gradient (Keller et al., 1977). Over 40 different chemokines 
have been discovered, which are categorized into families according to the position of the 
first two N-terminal cysteine (C) amino acid residues (Luster, 1998). “CC” chemokines 
exhibit adjacent cysteine residues, whereas one amino acid separates two cysteine 
residues in “CXC” chemokines (Luster, 1998). Chemokines are produced and secreted by 
immune cells, fibroblasts, endothelial cells and stromal cells throughout the body 
(Coondoo, 2011; Landskron, De la Fuente, Thuwajit, Thuwajit, & Hermoso, 2014). 
Chemokines bind to GPCRs on the cell surface; they may activate multiple receptors, and 
	   17 
each receptor may have more than one ligand (Teicher & Fricker, 2010). Chemokines 
exhibit autocrine, paracrine, or endocrine signalling mechanisms to induce chemotaxis 
(Coondoo, 2011; Schrader et al., 2002). Although the mechanism behind chemotaxis is 
not completely understood, intracellular signalling mechanisms likely cause chemotactic 
motility by promoting actin polymerization on one end of the cell, and myosin 
contraction on the opposite end (Levine & Rappel, 2013). This phenomenon creates a 
“pseudopod” which elongates the cell towards a chemoattractant or away from a 
chemorepellent (Levine & Rappel, 2013). Chemotaxis is especially crucial for regulating 
inflammation, tissue homeostasis, and embryonic development (Landskron et al., 2014).  
CXCL12 – also known as stromal-derived factor 1 (SDF-1) – is an 8-kilodalton 
chemokine that is widely distributed throughout the body (Shirozu et al., 1995). There 
exist two primary isoforms of CXCL12 – CXCL12a (i.e. SFD1-α), and CXCL12b (i.e. 
SDF1-β) – that result from alternative splicing of the same gene. CXCL12 is a potent 
chemoattractant, drawing responsive cells towards its highest concentration. CXCL12 
induces chemotaxis through binding to its receptor CXC receptor 4 (CXCR4) and is the 
only known ligand for this receptor (Jiang, Wu, Shi, Wu, & Yin, 2006). Although a 
second receptor for CXCL12 has been identified as CXC receptor 7 (CXCR7), it does not 
induce typical migratory responses upon activation (Burns et al., 2006; Naumann et al., 
2010). CXCR4 is mainly expressed on epithelial and endothelial cells, lymphocytes, 
hematopoietic stem cells and stromal fibroblasts, but can also be found on neurons, 
astrocytes, and glial cells (Guyon, 2014). 
CXCL12 guides cell migration in embryonic development, inflammation and 
wound healing. During embryogenesis, CXCL12 directs CXCR4+ progenitor cells 
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towards their final destination where they undergo differentiation (Cheng et al., 2014). 
This controls the development of the nervous, cardiovascular and hematopoietic systems 
(Barrientos et al., 2013; Li & Ransohoff, 2009; Tachibana et al., 1998; Zou, Kottmann, 
Kuroda, Taniuchi, & Littman, 1998). The CXCL12/CXCR4 axis also regulates 
inflammation and wound healing. CXCL12 recruits leukocytes and endothelium-
committed stem cells to the site of tissue damage for reparation (Kucia et al., 2004). 
1.3.1 CXCL12/CXCR4 Signalling in Cancer 
CXCR4 is the most commonly expressed chemokine receptor on cancer cells 
(Balkwill, 2004). Many types of cancers exhibit upregulated CXCR4 including breast, 
prostate, ovarian, pancreatic, esophageal, cervical, gastric, and head and neck squamous 
cell cancer, as well as leukemia and melanoma (Akashi et al., 2008; Muller et al., 2001; 
Richard & Blay, 2008; Scala et al., 2005). CXCR4 expression is particularly abundant in 
CRC. The receptor is highly expressed on human CRC cell lines (e.g. HT-29 and SW480 
cells) and moderately expressed on others (e.g. Caco-2 and LoVo cells) (Ottaiano et al., 
2005). CXCR4 is also overexpressed in human colorectal tumours compared to healthy 
colorectal tissues (Ottaiano et al., 2005).  
The overexpression of CXCR4 marks the progression of many different cancers. 
CXCR4 overexpression in colorectal tumours has predicted poor patient survival and risk 
of recurrence (Kim et al., 2005). It has also been positively correlated with the occurrence 
of metastasis to lymph nodes and distant organs (Schimanski et al., 2005). In cervical 
cancer CXCR4 overexpression in primary tumours has been associated with increased 
tumour size, lymph node metastasis, and decreased survival (Kodama et al., 2007). 
CXCR4 overexpression also correlates with reduced survival and increased metastasis in 
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patients with melanoma, head and neck squamous cell cancer, hepatocellular carcinoma, 
esophageal cancer, and prostate cancer (Darash-Yahana et al., 2004; Kaifi et al., 2005; 
Scala et al., 2005; Schimanski et al., 2006; Taki et al., 2008). CXCR4 may serve as a 
reliable prognostic marker for cancer patients. 
CXCL12 signalling may foster tumour growth and metastasis by a) promoting 
angiogenesis and b) directing primary tumour cell migration. One major function of the 
CXCL12/CXCR4 axis is blood vessel development and repair, thus it can also help 
vascularize a malignant tumour (Heidemann et al., 2004). CXCL12 stimulates the release 
of VEGF which causes the proliferation, migration and assembly of endothelial cells 
during angiogenesis (Guleng et al., 2005). CXCL12 also attracts endothelial cells to the 
site of angiogenesis (Orimo et al., 2005). Furthermore, CXCL12 may also promote 
metastatic spread by stimulating the directional migration of circulating tumour cells 
(Frick et al., 2011; Singh, Singh, Grizzle, & Lillard, 2004). It has been postulated that 
these CXCR4+ cells migrate towards organs rich in CXCL12 where they can form a 
secondary tumour (Chambers, Groom, & MacDonald, 2002). The most common sites for 
metastasis – the lung, liver, lymph nodes and bone marrow – express the highest levels of 
CXCL12, whereas the least common organs for metastasis express the lowest CXCL12 
levels (Muller et al., 2001).  
Decreasing CXCR4 expression and activity may impede metastasis. Silencing 
CXCR4 mRNA expression via small interfering RNA (siRNA) has inhibited CXCL12-
induced migration of colon cancer cells and breast cancer cells (Chen, 
Stamatoyannopoulos & Song, 2003; Frick et al., 2011; Liang et al., 2005). Silencing 
CXCR4 also decreased the number of lung metastases in mice inoculated with breast 
	   20 
cancer cells (Liang et al., 2004). Blocking CXCR4 activity with either CXCR4 
antagonists or anti-CXCR4 antibodies has inhibited breast cancer cell migration toward 
CXCL12 (Liang et al., 2004). CXCR4 antagonists have also reduced CXCL12-mediated 
migration of CRC cells (Li et al., 2008). Decreasing CXCR4 expression may impede 
metastasis by preventing cancer cell migration to distant organs.  
1.3.2 The Relationship Between Prostaglandins and CXCR4  
Prostaglandins may downregulate CXCR4 expression in CRC. An important 
study by Richard, Lowthers and Blay (2007) showed that J-series prostaglandins reduced 
CXCR4 mRNA and cell-surface protein expression on HT-29 CRC cells, and 15d-PGJ2 
exerted the most pronounced effect (Richard, Lowthers, & Blay, 2007). The effects of 
these prostaglandins on CXCR4 expression were likely achieved by altering the activity 
of transcription factors PPARγ and nuclear factor-κB (NFκB) (Richard, Lowthers & 
Blay, 2007). 15d-PGJ2 and synthetic PPARγ agonists were able to downregulate CXCR4 
expression to a similar degree, however the addition of PPARγ antagonists could not 
completely reverse this effect. The authors then showed that the cyclopentenone structure 
of J-series prostaglandins permitted the inhibition of NFκB, thereby suppressing the 
expression of the CXCR4 gene. Therefore, 15d-PGJ2 can downregulate CXCR4 
expression by activating PPARγ and inhibiting NFκB (Richard, Lowthers & Blay, 2007).  
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1.4 Dipeptidyl Peptidase IV/CD26  
 1.4.1 DPPIV/CD26 Structure and Function 
 
Dipeptidyl peptidase IV (DPPIV), or CD26, is a transmembrane protease that has 
several important functions in the tissue microenvironment. The enzyme is primarily 
anchored to the outer membrane of most mammalian cells, but also resides in the cytosol 
and nucleus to a lesser extent (Mccaughan, Wickson, Creswick, & Gorrell, 1990; 
Yamada et al., 2009). It contains a short cytoplasmic domain, a transmembrane domain, 
and a relatively large extracellular domain (Figure 1.5). The extracellular domain is the 
site of enzymatic activity and contains a) a glycosylation site, b) a cysteine-rich site that 
binds collagen and fibronectin, as well as adenosine deaminase (ADA), and c) a catalytic 
site that cleaves certain polypeptides (Huhn, Ehrlich, Fleischer, & von Bonin, 2000; 
Kameoka, Tanaka, Nojima, Schlossman, & Morimoto, 1993; Piazza, Callanan, Mowery, 
& Hixson, 1989). DPPIV is also referred to as cluster of differentiation antigen 26 
(CD26) and adenosine deaminase binding protein (ADAbp) since these proteins were 
discovered to be structurally homologous to DPPIV (Darmoul et al., 1991; Morrison, 
Vijayasaradhi, Engelstein, Albino, & Houghton, 1993). The designation “DPPIV” 
typically refers to its enzymatic activity. DPPIV/CD26 has been investigated for its 
potential role in cancer due to its multifunctional nature and its differential expression on 
cancer cells versus healthy cells, as discussed below. 
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Figure 1.5: Dipeptidyl peptidase IV/CD26 within the plasma membrane.	  
(Reproduced from Blay, 2008 with permission). 
1.4.2 DPPIV/CD26 Expression and Distribution 
 
Dipeptidyl peptidase IV/CD26 is ubiquitously expressed in normal tissues. 
Epithelial cells primarily express DPPIV/CD26, yet the enzyme is also found on T- and 
B-lymphocytes, fibroblasts and endothelial cells (Mccaughan et al., 1990). DPPIV/CD26 
is distributed within most mammalian tissues and organs, and the level of expression 
depends on the type of tissue and the location within that tissue (Abott, Baker, Sutherland 
& McCaughan, 1995; Hartel, Gossrau, Hanski & Reutter, 1988). The enzyme is 
constitutively expressed in the kidney, small intestine and liver (Kettmann, Humbel, & 
Holzhausen, 1992). The brush border membranes of epithelial cells in the kidney cortex 
and small intestine strongly express DPPIV/CD26 (Stange, Kettmann, & Holzhausen, 
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1996). In the small intestine, the ileum and jejunum exhibit the highest DPPIV/CD26 
expression and DPPIV activity (Darmoul et al., 1994). In the liver, DPPIV/CD26 is found 
on the bile duct epithelia, and on hepatocytes around the bile caniculi (Fukasawa et al., 
1981; Hartel et al., 1988). The enzyme is also expressed in small amounts on colon 
epithelial cells (Dinjens et al., 1989). Furthermore, DPPIV/CD26 is also situated on 
epithelial cells lining the sweat, adrenal, prostate and salivary glands (Sahara & Suzuki, 
1984). In the cardiovascular system, DPPIV/CD26 is expressed on endothelial cells that 
comprise the capillary beds of the lung, spleen, pancreas, myocardium and blood-brain 
barrier (Hartel et al., 1988; Lojda, 1979). Soluble DPPIV/CD26 (sDPPIV), which only 
consists of its extracellular domain, is dissolved in blood plasma, urine, amniotic fluid, 
semen and synovial fluid (Durinx et al., 2000). sDPPIV retains its binding capacity and 
peptidase activity (Durinx et al., 2000).  
1.4.3 DPPIV Dipeptidase Activity of DPPIV/CD26 
 
Dipeptidyl peptidase IV selectively removes an N-terminal dipeptide from many 
natural polypeptides (Figure 1.6) (Mentlein, Gallwitz, & Schmidt, 1993). Substrates with 
proline or alanine at the penultimate position (P1) – the second residue from the N-
terminus – are cleaved with the highest catalytic efficiency (Mentlein et al., 1993). 
However, proline-containing substrates are preferred. Other substrates that are cleaved 
less efficiently may contain hydroxyproline, dehydroproline, serine, glycine, valine, 
threonine or leucine at P1 (de Meester, Lambeir, Proost, & Scharpe, 2003). The 
dipeptidase activity of DPPIV/CD26 is primarily studied through its cleavage of synthetic 
chromogenic or fluorogenic substrates such as Gly-Pro-p-nitroanilide and Ala-Pro-cresyl 
violet, respectively.   
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Dipeptidyl peptidase IV/CD26 can either suppress or enhance the activity of its 
substrates upon cleavage, thereby adjusting the bioactivity of many regulatory 
polypeptides in the body (de Meester et al., 2003). DPPIV/CD26 cleaves a diverse range 
of bioactive substrates including cytokines, chemokines, growth factors, peptide 
hormones and neuropeptides (Table 1.2). Consequently, the enzyme modulates a broad 
range of physiological processes including development, immune and inflammatory 
responses, blood vessel dilation and constriction, hunger, energy homeostasis, and 
digestion (Blay, 2008). Targeting the dipeptidase activity of DPPIV/CD26 may confer 
diverse therapeutic advantages.  
  Dipeptidyl peptidase IV/CD26 degrades numerous chemokines with different 
levels of efficiency. The chemokine that is degraded with the highest catalytic efficiency 
is CXCL12, which contains a proline penultimate residue (Lambeir et al., 2001). 
DPPIV/CD26 truncates CXCL12 and terminates its bioactivity (De La Luz Sierra et al., 
2004; Shioda et al., 1998). As a result, CXCL12-mediated chemotaxis is impeded 
(Shioda et al., 1998). CXCL12 inactivation by DPPIV/CD26 has reduced the migration 
of hematopoietic and progenitor cells in vitro, and inhibiting DPPIV dipeptidase activity 
on these cells restored their ability to migrate (Christopherson, Hangoc, & Broxmeyer, 
2002). Cleavage of CXCL12 by DPPIV/CD26 may contribute to the regulation of cell 
migration in the body.  
Dipeptidyl peptidase IV/CD26 may impede metastasis by decreasing CXCL12-
mediated cell migration. CXCL12 activity is upregulated in various types of cancer 
(Liekens, Schols, & Hatse, 2010). The CXCL12/CXCR4 axis facilitates metastasis by 
directing primary tumour cells to secondary organs and tissues (Vandercappellen, Van 
	   25 
Damme, & Struyf, 2008). Reducing bioavailable CXCL12 via DPPIV/CD26 has been 
shown to downregulate cancer metastasis in vivo (Sun et al., 2008). In one study by Sun 
et al. (2008) the authors modelled metastasis by establishing primary tumours in 
immunodeficient mice and subsequently measuring the number of primary tumour cells 
that migrated into different tissues. Mice that were treated with the DPPIV/CD26 
inhibitor diprotin A exhibited significantly more primary tumour cells in the brain, lymph 
nodes, mandible, humerus and tibia than mice that were treated with the vehicle control. 
The authors concluded that DPPIV/CD26 inhibited cancer cell migration likely through 
its degradation of CXCL12 (Sun et al., 2008).  
 
 
Figure 1.6: DPPIV/CD26 dipeptidase activity. 	  
DPPIV/CD26 cleaves the peptide bond after the penultimate (P1) residue. Possible P1 
amino acid (AA) residues include proline (Pro), alanine (Ala), serine (Ser), glycine (Gly), 
valine (Val), threonine (Thr) and leucine (Leu). Catalytic efficiency of the substrate 
decreases with decreasing font. (Adapted from Klemann, Wagner, Stephan & von 
Horsten, 2016). 
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Molecule Full name and main function 
CXCL12 SDF-1α (stromal cell-derived factor-1α); Involved in the 
development of the nervous system, bone marrow and intestine, 
and in the homing of stem cells. 
CCL22 Macrophage-derived chemokine; An attractant for various 
types of white cells and functions in immune and inflammatory 
responses. 
GRP Gastrin releasing peptide; Released by nerves in the stomach to 
cause the production of gastrin from G cells in the mucosa. 
NPY Neuropeptide Y; Peptide neurotransmitter found in the brain 
that regulates normal physiological processes such as hunger, 
energy homeostasis and blood pressure. 
GLP-1 Glucagon-like peptide-1; Gut hormone secreted by L cells in 
the intestine, has a role in control of insulin levels. 
CCL11 The chemokine Eotaxin-1; Causes the recruitment of 
eosinophils into tissues and plays a role in allergic responses. 
CCL5 The chemokine RANTES (‘Regulated on Activation, Normal 
T Expressed and Secreted’); Selective attractant for memory T 
lymphocytes and monocytes. 
VIP Vasoactive intestinal peptide; Peptide hormone produced by 
various tissues, with effects on blood vessels and secretory 
processes. 
Table 1.2: Some of the major substrates for dipeptidyl peptidase IV and their activities in 
human tissues. 
(Reproduced from Blay, 2008 with permission). 
 
1.4.4 DPPIV/CD26 Dipeptidase Activity in Diabetes 
The dipeptidase activity of DPPIV/CD26 is also implicated in type II diabetes. 
Common DPPIV/CD26 substrates are incretins (e.g. glucagon-like peptide-1 (GLP-1), 
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glucose-dependent insulinotropic polypeptide (GIP)) which are intestinal polypeptides 
that promote the secretion of insulin, and thus lower blood glucose levels (Green, Flatt & 
Bailey, 2006; Nielsen, 2005). DPPIV/CD26 rapidly degrades incretins, inhibiting their 
effect on insulin release (Green, Flatt & Bailey, 2006; Nielsen, 2005). DPPIV inhibitors 
called gliptins prevent the degradation of incretins, thereby increasing insulin levels in 
the blood and thus lowering blood glucose levels in diabetic patients (Green, Flatt & 
Bailey, 2006; Nielsen, 2005).  
1.4.5 DPPIV/CD26 and Cell Adhesion  
 
 Another major function of DPPIV/CD26 is promoting cell adhesion. Cell 
adhesion is the process by which cells associate with each other and with the ECM (Zhu, 
Bao, & Wang, 2000). The ECM is a dynamic network of macromolecules outside the cell 
that provides structural and biochemical support (Bosman & Stamenkovic, 2003). Two 
abundant fibrous proteins within the ECM are collagen and fibronectin (Bosman & 
Stamenkovic, 2003). Fibronectin anchors cells to collagen to promote adhesion to the 
ECM (Klebe, 1974). Cell-surface DPPIV/CD26 binds to both collagen and fibronectin, 
serving as an additional anchor to the ECM (Hanski, Huhle, Gossrau, & Reutter, 1988). 
In fact, the cysteine-rich region of DPPIV/CD26 has specific binding sites for collagen 
and fibronectin that are distinct from the catalytic domain (H. C. Cheng, Abdel-Ghany, & 
Pauli, 2003; Loster, Zeilinger, Schuppan, & Reutter, 1995).   
Dipeptidyl peptidase IV/CD26 may prevent metastasis by suppressing the 
migration of primary tumour cells. DPPIV/CD26 overexpression has been associated 
with increased cell-cell adhesion, and reduced migration and invasive potential of ovarian 
carcinoma cells (Inamoto et al., 2007; Kikkawa et al., 2005). Furthermore, inducing 
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DPPIV/CD26 expression in non-small cell lung cancer cell lines has been shown to 
reduce their migration on both fibronectin- and collagen-coated chambers by 50 to 75% 
(Wesley, Tiwari, & Houghton, 2004).  
 1.4.6 DPPIV/CD26 and Extracellular Adenosine 
 
Dipeptidyl peptidase IV/CD26, or ADAbp, also promotes the breakdown of 
extracellular adenosine. DPPIV/CD26 has a distinct binding site for adenosine deaminase 
(ADA) – an enzyme that catalyzes the irreversible metabolism of the nucleosides 
adenosine and 2’deoxyadenosine (Brady, 1942; Spencer, Hopkinson, & Harris, 1968). 
DPPIV/CD26 and ADA co-localize on the cell surface to augment the deamination of 
adenosine (Dong et al., 1996). Deamination inactivates these nucleosides and prevents 
their accumulation in the extracellular fluid (Spencer et al., 1968).  
Metabolizing adenosine may impede cancer progression. Extracellular adenosine 
can promote tumour survival and growth by suppressing cell-mediated immune 
responses. The nucleoside prevents the activation and proliferation of lymphocytes, and 
can also be cytotoxic to lymphocytes (Hovi, Smyth, Allison, & Williams, 1976). 
Furthermore, adenosine can promote metastasis by stimulating cancer cell motility and 
proliferation as well as angiogenesis (Hasko & Cronstein, 2004; Mujoomdar, Bennett, 
Hoskin, & Blay, 2004; Mujoomdar, Hoskin, & Blay, 2003; Woodhouse et al., 1998) 
(Barcz, Sommer, Janik, Marianowski, & Skopinska-Rozewska, 2000; Olah & Caldwell, 
2003). The extracellular fluid of solid tumours in mice has exhibited high levels of 
extracellular adenosine (Blay, White, & Hoskin, 1997). Interestingly, high levels of 
adenosine can decrease DPPIV/CD26 expression and ADA binding in CRC cells (Tan et 
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al., 2006). The relationship between adenosine and DPPIV/CD26 may provide insight 
into the metastatic progression of cancer. 
1.4.7 DPPIV/CD26 and the Immune Response 
DPPIV/CD26 also regulates the immune response through T lymphocyte 
activation (Gorrell, Gysbers, & McCaughan, 2001). T lymphocytes are a subpopulation 
of white blood cells that become activated in response to an antigen, and subsequently 
trigger immunologic processes (Reinherz & Schlossman, 1980). T cell-surface expression 
of DPPIV/CD26 increases after antigenic stimulation, and these activated CD26+ 
lymphocytes rapidly proliferate to induce a robust immune response (Ulmer, Mattern, & 
Flad, 1992). Upregulated DPPIV/CD26 expression on the cell surface is therefore 
considered a marker of T cell activation. This effect may influence immunosurveillance 
in the TME. 
1.4.8 DPPIV/CD26 Expression in Cancer 
 
Dipeptidyl peptidase IV/CD26 expression is highly variable in cancer. The 
enzyme is upregulated in some cancers and downregulated in others. Malignant 
mesothelioma and prostate cancer tissues have both shown significantly higher 
DPPIV/CD26 expression than their respective benign tissues (Inamoto et al., 2007; 
Wilson et al., 2000). Renal carcinoma cells have also exhibited upregulated DPPIV/CD26 
expression compared to healthy cells (Inamoto et al., 2006). Meanwhile, a 
downregulation in DPPIV/CD26 expression has been reported in melanoma, endometrial 
cancer, liver cancer, and non-small cell lung cancer (Houghton, Albino, Cordon-Cardo, 
David & Eisinger, 1988; Khin et al., 2003; Stecca et al., 1997; Wesley et al., 2004).  
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Dipeptidyl peptidase IV/CD26 can also exhibit variable expression within one cancer 
type. Findings on DPPIV/CD26 expression in colorectal, prostate and ovarian cancer are 
inconsistent across the literature (Havre et al., 2008). Several studies have shown 
considerable variation in DPPIV/CD26 abundance and localization between different 
colorectal tumours, and between cells within one colorectal tumour (Ten Kate, 
Vandeningh, Khan & Bosman, 1986; Ten Kate et al., 1985). Furthermore, the amount of 
soluble DPPIV/CD26 (sCD26) dissolved in the blood plasma of CRC patients also varied 
between studies. Cordero et al. (2000) found reduced sCD26 levels in CRC patients, 
whereas de la Haba-Rodriguez et al. (2002) reported upregulated sCD26, with the highest 
levels present in patients with metastatic CRC. Although the differential expression of 
DPPIV/CD26 in CRC is still being elucidated, it might be explained by the level of 
differentiation of the carcinoma, as well as the heterogeneity of cell subpopulations in the 
tumour (Kate, Vandeningh, Khan & Bosman, 1986).  
The prognostic significance of DPPIV/CD26 expression also varies between 
different cancers. In some cancers, DPPIV/CD26 expression is positively correlated with 
improved patient prognosis. For instance, overexpressed DPPIV/CD26 in malignant 
pleural mesothelioma tumours has been associated with prolonged patient survival (Aoe 
et al., 2012). DPPIV/CD26 overexpression has also been correlated with reduced prostate 
cancer metastasis (Bogenrieder et al., 1997). In contrast, DPPIV/CD26 overexpression is 
associated with metastasis in several types of cancer. Lam et al. (2014) found that 
DPPIV/CD26 expression was higher in primary tumours of patients with metastatic CRC 
than patients with local CRC, and DPPIV/CD26 overexpression indicated worse patient 
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survival. Worse patient survival has also been correlated with increased levels of 
DPPIV/CD26 in ovarian tumours (M. Z. Zhang, Qiao, & Suo, 2008). 
Increasing DPPIV/CD26 expression in vitro has been shown to reduce the 
metastatic activity of some cancers. For example, a study by Kajiyama et al. (2002) 
reported that CD26+ ovarian carcinoma cells showed less migration and invasion than 
CD26- ovarian carcinoma cells. The authors also found a correlation between 
DPPIV/CD26 overexpression and a prolonged survival time of nude mice inoculated with 
CD26-positive ovarian carcinoma cells. Furthermore, transfecting CD26 into melanoma 
cells has reduced their invasiveness by 75% (Pethiyagoda, Welch, & Fleming, 2001). 
Dipeptidyl peptidase IV/CD26 expression and activity in cancer probably depends 
on multiple parameters. Since DPPIV/CD26 exhibits pleiotropic effects between different 
tissues, its effect on cancer progression likely depends on the location of the tumour 
(Blay, 2008). In fact, a study on differential gene expression in the colon reported 
significantly higher DPPIV/CD26 mRNA levels in right-sided than left-sided colorectal 
tumours (Fric et al., 2000). Second, the level of differentiation of the cancer ought to be 
considered.  Darmoul et al. (1992) found that DPPIV/CD26 expression on HT-29 and 
Caco-2 CRC cells positively correlated with their degree of differentiation. Sakamoto et 
al. (1993) also found high DPPIV/CD26 expression in well-differentiated cancers, 
whereas its expression was virtually absent in poorly differentiated cancers. Finally, 
studies on DPPIV/CD26 expression vary greatly in the methods by which they detected 
the enzyme, with some methods being more sensitive than others. 
 
 
	   32 
1.4.9 The Relationship Between DPPIV/CD26 and CXCR4 
 
 Dipeptidyl peptidase IV/CD26 and the chemokine receptor CXCR4 are related in 
several ways. First, DPPIV/CD26 degrades and inactivates the CXCR4 ligand CXCL12 
with high affinity (Lambeir et al., 2001). DPPIV/CD26 and CXCR4 also exhibit an 
inverse relationship; the cell-surface expression of CXCR4 has shown to decrease with 
increased DPPIV/CD26 expression, and vice versa (Cutler et al., 2015; Tan et al., 2006; 
Richard, Tan & Blay, 2006; Kajiyama et al., 2007). The administration of 
chemotherapeutic agents to CRC cells increases cell-surface levels of DPPIV/CD26 
while simultaneously downregulating CXCR4 (Cutler et al., 2015). The maximum 
decrease in CXCR4 averaged to 78.6% between different anticancer drug treatments, 
while the maximum increase in DPPIV/CD26 ranged from 22.4% to 72.1%. Furthermore, 
treating HT-29 CRC cells with adenosine has both suppressed CXCR4 expression and 
upregulated DPPIV expression and activity in separate studies (Tan et al., 2006; Richard, 
Tan & Blay, 2006). On the contrary, a concomitant decrease in DPPIV/CD26 and 
increase in CXCR4 expression has been observed in human peritoneal mesothelial cells 
in response to transforming growth factor-β1 treatment (Kajiyama et al., 2007).  
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1.5 Rationale of the Project 
 
 Dipeptidyl peptidase IV/CD26 regulates several anti-metastatic activities in the 
tumour microenvironment. Although DPPIV/CD26 has shown variable expression in 
CRC, upregulation of the enzyme may suppress metastasis by (i) decreasing extracellular 
adenosine, (ii) promoting cellular adhesion to the extracellular matrix, and (iii) degrading 
the pro-tumorigenic chemokine CXCL12. It is unclear why DPPIV/CD26 expression 
varies in CRC, although tissue factors likely play a role. However, DPPIV/CD26 
expression and activity have shown to increase with a concurrent decrease in CXCR4 in 
response to various treatments. CXCR4 expression on colorectal cancer cells can be 
downregulated by several J-series prostaglandins (particularly 15d-PGJ2). Therefore, we 
investigated whether such prostaglandin treatment conversely upregulates DPPIV/CD26 
levels on CRC cells (Figure 1.7). Upregulated DPPIV/CD26 would likely suppress the 
metastatic potential of CRC cells. 
 
Figure 1.7: The relationship between prostaglandins, CXCR4 and DPPIV/CD26 in the 
tumour microenvironment. 	  
J-series prostaglandins (PGJs) have shown to downregulate CXCR4 expression on CRC 
cells. Downregulated CXCR4 expression has been previously associated with an increase 
in DPPIV expression and activity. Increased DPPIV may also occur with J-series 
prostaglandin (PGJ) treatment. 
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2. Objectives and Hypothesis 
2.1. Objectives 
 
The specific objectives of my project were to: 
 
1. Quantify changes in DPPIV/CD26 dipeptidase activity on colon carcinoma cells 
in response to prostaglandin treatment. 
2. Identify changes in DPPIV/CD26 mRNA and protein expression in colon 
carcinoma cells in response to prostaglandin treatment. 
3. Determine changes in cell-ECM interactions due to prostaglandin treatment on 
colon cancer cells. 
 
2.2. Hypothesis 
 Prostaglandin treatment will induce an upregulation in DPPIV/CD26 expression 
and activity on colon carcinoma cells, and this will increase the DPPIV/CD26-mediated 
cellular interactions with the extracellular matrix.  
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3. Materials and Methods 
 
3.1 Materials 
 
HT-29 and Caco-2 human colon carcinoma cells, and NIH3T3 mouse fibroblasts, 
were obtained from the American Type Culture Collection (Manassas, VA). Culture 
flasks and 96- and 24-well plates (Nunc™), as well as media (HyClone Laboratories Inc.) 
and trypsin-EDTA (0.25%) (Gibco™) were from ThermoFisher Scientific (Mississauga, 
ON, Canada). Fetal bovine serum (FBS) was from VWR International (Mississauga, ON, 
Canada) and newborn calf serum (NCS) was from ThermoFisher Scientific (Mississauga, 
ON, Canada). 15d-PGJ2, PGJ2, PGD2 and PGF2α were from Cayman Chemical (Ann 
Arbor, MI, USA). Dimethyl sulfoxide (DMSO) (Fisher Bioreagents™) was from Fisher 
Scientific (Mississauga, ON, Canada). Gly-Pro-p-nitroanilide (Gly-Pro-pNA) DPPIV 
substrate and bovine serum albumin (BSA) were from Sigma-Aldrich (Oakville, ON, 
Canada), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer 
(Fisher BioReagents™) was from Fisher Scientific (Mississauga, ON, Canada). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Alfa Aesar™) was 
obtained from Fisher Scientific (Mississauga, ON, Canada). 
Tris(hydroxymethyl)aminomethane (TRIS) buffer (AMRESCO Inc.) was from VWR 
International (Mississauga, ON, Canada). Bio-Rad Protein Assay Dye Reagent was from 
BioRad Laboratories (Mississauga, ON, Canada). Protein inhibitors 
phenylmethylsulfonyl fluoride (PMSF) and leupeptin (Tocris Bioscience), as well as 
aprotinin (Cayman Chemical) were from Cedarlane Laboratories (Burlington, ON, 
Canada). Ethylenediaminetetraacetic acid (EDTA), glycine, glycerol and Tween 20 were 
purchased from Fisher Scientific (Mississauga, ON, Canada). Triton X-11, p-coumaric 
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acid and luminol were purchased from Sigma-Aldrich (Oakville, ON, Canada). 96-well 
polypropylene plates and the C18 high performance liquid chromatography (HPLC) 
column were from Agilent Technologies (Mississauga, ON, Canada). Chloroform and 
HPLC-grade acetonitrile were purchased from Sigma Aldrich (Oakville, ON, Canada). 
LCMS-grade trifluoroacetic acid was from CovaChem LLC (Loves Pak, IL, USA). TRI 
Reagent® and potassium acetate were purchased from Sigma-Aldrich (Oakvilla, ON, 
Canada). First strand (FS) buffer, dithiothreitol (DTT), RNAse Out® and Moloney 
Murine Leukemia Virus (M-MLV) were from Invitrogen Canada (Burlington, ON, 
Canada). Oligo deoxythymine (dT) and CD26 and GAPDH polymerase chain reaction 
(PCR) primers (Jena Bioscience) were from Cedarlane Labs, and deoxynucleotide 
triphosphate (dNTP) mix was from ThermoScientific (Mississauga, ON, Canada). SSO 
Advanced SYBR Green quantitative PCR (qPCR) Mix was from BioRad Laboratories 
(Mississauga, ON, Canada).  
3.2 Antibodies and Primers 
 3.2.1 Antibodies 
For Western blot experiments, rabbit monoclonal antibodies (mAb) against 
human CD26 (clone EPR5883), and mouse mAb (HRP conjugated) against human ß-
actin (clone mAbcam 8226) were from Abcam Inc. (Toronto, ON, Canada). Goat anti-
rabbit IgG (HRP-conjugated) was purchased from Invitrogen Canada (Burlington, ON, 
Canada). For immunofluorescence experiments, rabbit polyclonal antibodies (pAb) 
against human CD26 were purchased from Abcam Inc. (Toronto, ON, Canada). Alexa 
Fluor® 488 conjugated goat anti-rabbit IgG was obtained from Invitrogen Canada 
(Burlington, ON, Canada). 
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3.2.2 Primers 
 
DNA primer sets for PCR and qPCR were obtained from Invitrogen Canada 
(Burlington, ON, Canada) and had the following sequences: 
 
1. CD26:   Forward: 5’-CTCACTTCCGAGGAGACGCC-3’ 
   Reverse: 5’-TCATCTGTGCCTTTGTTCAGCAGA-3’ 
2. GAPDH:  Forward: 5’-CGACCACTTTGTCAAGCTCA-3’ 
   Reverse: 5’-AGGGGTCTACATGGCAACTG-3’ 
3.2.3 Primer Selection 
 
Short DNA primers were used in PCR and qPCR experiments to identify DNA 
fragments of CD26. Primers were designed using the National Center for Biotechnology 
Information (NCBI) PrimerBLAST program. Criteria for primer selection were based on 
recommendations from the StepOnePlus PCR manual (Applied Biosystems). 2000 
primers were screened for a size between 18-25 base pairs, an amplicon length between 
80-250 base pairs, a melting temperature (Tm) between 58-61°C, and a 30-80% G/C 
content with a maximum of 3 G and/or C bases within the five nucleotides on the 3’ end. 
The maximum mononucleotide repeat (max poly-X) score, self-complementarity score, 
and template mispriming score were minimized (5 or lower). Selected primers fulfilled 
most, if not all, of the above criteria.  
3.3 Cell Culture 
 
HT-29, Caco-2 and NIH3T3 cell lines were maintained as stocks in 20-cm2 flasks 
and incubated at 37°C in a humidified atmosphere of 90% air/10% CO2. Cells were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) (without antibiotics) with 1% 
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sodium pyruvate, supplemented with either 5% or 10% v/v heat-inactivated fetal bovine 
serum (FBS) (HT-29 and Caco-2 cells), or 10% v/v heat-inactivated newborn calf serum 
(NCS) (HT-29 cells and NIH3T3 cells). Cells were subcultured when approximately 80% 
confluent and split at a 1:5 ratio. 
Cells were treated with specific concentrations of one prostaglandin when 
approximately 70% confluent (although in some experiments cells were treated when 
grown to confluence). The vehicle for all prostaglandins was dimethyl sulfoxide (DMSO) 
at a final concentration at or below 0.2% v/v. Prostaglandins 15d-PGJ2, PGJ2, PGD2 and 
PGF2α were stored as 20 mM stocks at -80˚C. Concentrations of prostaglandins were 
prepared so that each treatment contained the same amount of DMSO.  
3.4 DPPIV/CD26 Enzyme Activity Assay 
A chromogenic assay was used to measure DPPIV/CD26 dipeptidase activity. 
HT-29 cells were seeded in a 24-well flat-bottomed plate at a density of 5 x 104 cells. The 
cells were then treated with different concentrations of one prostaglandin and incubated 
at 37˚C for 48 h. After incubation, the plate was placed on ice, the media was aspirated, 
and the wells were washed 3 x with 500 µL ice-cold PBS (0.8% NaCl, 0.02% KCl, 
0.12% Na2HPO4, 0.02% KH2PO4 m/v in distilled water; pH 7.4) with Ca2+ and Mg2+. 
Cells were then subjected to the chromogenic DPPIV substrate Gly-Pro-p-nitroanilide 
(Gly-Pro-pNA). 2 mM of Gly-Pro-pNA was prepared in 100 mM HEPES buffer (pH 7.6) 
with 0.12 M NaCl, 5 mM KCl, 1.2 mM MgSO4, 8 mM glucose and 10 mg/mL bovine 
serum albumin (BSA). 250 µL of this Gly-Pro-pNA solution was added to each well, and 
the plate was incubated at 37˚C for 2 h. Cleavage of Gly-Pro-pNA by DPPIV yielded the 
product pNA, which transforms the clear solution into a yellow colour. 100 µL of yellow 
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supernatant was transferred into a 96-well flat-bottomed plate, and the absorbance was 
measured by a SpectraMax® microplate reader at 405 nm. The absorbance indicates the 
amount of yellow pNA product. The amount of product is proportional to the amount of 
DPPIV dipeptidase activity.  
3.5 MTT Assay 
 
 An MTT assay was performed to measure cell viability in response to 
prostaglandin treatment. Cells were seeded in a flat-bottomed 96-well plate at a density of 
5 x 104 cells. Cells were treated with different concentrations of one prostaglandin for 48 
h, after which they were subjected to the tetrazolium dye precursor MTT. MTT is 
reduced to a purple formazan crystal by mitochondrial enzymes within viable cells. 5 
mg/mL MTT was prepared in PBS, which was then vortexed and passed through 
Whatman® filter paper to remove particulates. 20 µL MTT reagent was pipetted into 
each well, and the plate was mixed for 5 min on a plate rotator and then incubated at 
37°C for 2 h. The plate was then carefully inverted over an absorbent pad to remove the 
media without losing cells. The formazan crystal that resulted from MTT reduction was 
solubilized in 100 µL DMSO, and the plate was incubated at RT on a platform shaker for 
30 min. During this time the plate was wrapped in aluminum foil to avoid exposure to 
light. Absorbance of the formazan product was measured on a SpectraMax® microplate 
reader at 492 nm. Absorbance was correlated with the relative amount of viable cells.  
3.6 Cell Counting Assay 
 
 Cells were counted to measure cell viability in response to prostaglandin 
treatment. Cells were seeded in a flat-bottomed 24-well plate at a density of 5 x 104 cells 
and treated with various concentrations of a prostaglandin for 48 h. Then, the 24-well 
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plate was washed 3 x with 500 µL PBS. 500 µL trypsin-EDTA was added to each well 
and the plate was incubated at 37˚C for 10 min. 500 µL of the trypsin-EDTA was then 
thoroughly pipetted up and down to ensure complete dissociation of cells, and then 
transferred into a cuvette containing 9.5 mL PBS. The cuvette was placed in the digital 
multisizer (Beckman Multisizer™ 4) for cell counting. Three cell count values were 
taken for each sample. 
3.7 Western Blot 
3.7.1 Protein Collection 
 
 HT-29 cells were seeded in 25 cm2 flasks at a density of 7 x 105 cells. Cells grew 
until approximately 70% of confluence, after which they were treated with a 
prostaglandin at different concentrations for either 24 h or 48 h depending on the 
experiment. After treatment, the flasks were placed on ice and washed twice with 5 mL 
PBS containing Ca2+ and Mg2+ to remove dead cells and debris without disrupting the 
monolayer. 500 µL RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, 1% Triton X-100, 
0.5% sodium deoxycholate, 0.1% SDS in 1 mM EDTA; pH 8.0) with protease inhibitors 
(1 mM PMSF freshly added, 5 mM EDTA, 1 µg/mL aprotinin and 5 µg/mL leupeptin) 
was added to each flask, and the flasks were incubated at 4˚C on a plate rotator for 30 
min. The lysate was pipetted 10 x to detach proteins from the monolayer, and collected 
into separate 2 mL tubes. The tubes were centrifuged at 14,000 x g and 4˚C for 20 min to 
pellet the membranes, nuclear material and cytoskeletal proteins. 400 µL of the 
supernatant was then carefully transferred into fresh 2 mL tubes and stored at -80˚C 
overnight.   
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3.7.2 Bradford Assay 
 
 The Bradford assay was used to measure the relative concentration of protein 
within the collected protein samples. 5 µL of bovine serum albumin (BSA) protein 
standards (0, 50, 125, 250, 375, 500, 750 and 1000 µL/mg) were pipetted in triplicate into 
a flat-bottomed 96-well plate to generate a standard concentration curve. 0.5 µL of 
collected protein sample was pipetted in triplicate and diluted 1/10 with 10% RIPA buffer 
and 80% distilled water. Using a multichannel pipette, 200 µL of Bradford Dye Reagent 
was dispensed into each well, which turns blue upon protein binding. The absorbance of 
blue product was read spectrophotometrically on a SpectraMax® microplate reader at 
595 nm. The absorbance value was correlated with the amount of protein in the sample. 
Sample concentrations were equalized by diluting them in RIPA buffer accordingly.  
3.7.3 SDS-PAGE 
 
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
conducted to separate proteins by molecular weight. 100 µL of protein sample was 
transferred into a fresh tube and combined with 100 µL 2X Laemmli sample buffer [0.5 
M Tris-HCl (pH 6.8), 10% glycerol, 2% SDS, 5% 2-beta-mercaptoethanol, 0.01% 
bromophenol blue]. Samples were vortexed for 20 s, and then boiled for 5 min to 
denature proteins. Equal volumes of sample protein were loaded into each lane of the 4% 
stacking/7.5% resolving polyacrylamide gel. The gel was run in running buffer (5.1 mM 
SDS, 25 mM Tris base, 0.192 M glycine, 2% methanol in distilled water; pH ~8.3) and 
samples were separated by electrophoresis at 10 mA per gel for approximately 4 h.  
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3.7.4 Transfer and Immunoblotting 
 
 After the proteins were separated by SDS-PAGE, the gel was transferred onto a 
polyvinylidene difluoride (PVDF) membrane using the wet transfer method. For the wet 
transfer method, the gel was equilibrated in transfer buffer (192 mM glycine, 25 mM Tris 
base in methanol, pH 8.3) for 15 min and the PVDF membrane was equilibrated in 
methanol. The protein samples were electroblotted in transfer buffer at 10 V for 16 h at 
4˚C.  
Blotted membranes were blocked with 3% BSA m/v in 20 mL Tris-buffered 
saline (TBS) (50 mM Tris base, 150 mM NaCl in distilled water; pH 7.6) with 0.1% 
Tween 20 (TBS-T) for 1 h at RT. Membranes were washed with 20 mL TBS-T for 5 min 
on a plate rotator, and then probed with 10 mL primary antibody for 2 h at RT. 
Antibodies were diluted in TBS-T with 1% BSA m/v; primary antibody dilutions were 
1:50,000 for anti-CD26 and 1:1,000 for anti-ß-actin. The blotted membranes were then 
washed 3 x 5 min with 20 mL TBS-T, and then probed with 10 mL secondary antibody 
for 1 h at RT. Secondary antibodies were horseradish peroxidase (HRP)-conjugated, and 
the dilutions for anti-mouse and anti-rabbit IgG secondary antibodies were 1:2000. The 
membranes were then washed 4 x 5 min with 20 mL TBS-T. Protein bands were 
visualized using enhanced chemiluminescence; each membrane was exposed to 1.5 mL 
of chemiluminescence solution [100 mM Tris-HCl (pH 8.5), 200 µM p-coumaric acid, 
1.25 mM luminol, 0.01% H2O2] for 5 min. Images of the membrane were captured using 
a Kodak™ Image Station 4000 mm Pro at exposure times ranging from 30 s to 3 min. 
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3.8 Immunofluorescence 
 
 The localization of DPPIV/CD26 on HT-29 cells was visualized using 
immunofluorescence. Cells were seeded into an 8-well chamber slide in 500 µL DMEM 
supplemented with 10% NCS, and grown to 30% of confluence. Each well was then 
exposed to a prostaglandin for 48 h. The media was then carefully aspirated using a 
capillary pipette, and the wells were washed with 200 µL PBS with Ca2+ and Mg2+. The 
cell monolayer was then fixed onto the slide using freshly prepared 1% paraformaldehyde 
(PFA). The monolayer was exposed to 200 µL 1% PFA for 10 min at RT, then washed 
three times with 200 µL PBS with Ca2+ and Mg2+. To prevent nonspecific antibody 
binding, the monolayer was then exposed to 200 µL 3% BSA for 30 min at RT. The BSA 
solution was then aspirated, and 200 µL of CD26 primary antibody in 1% BSA in PBS 
with Ca2+ and Mg2+ (1:150 dilution) was added to each well. The wells were incubated 
for 90 min at RT. The wells were then washed three times for 5 min with 1% BSA in 
PBS with Ca2+ and Mg2+ on a rotary platform mixer. 200 µL 488-Alexafluor fluorophore-
conjugated anti-rabbit secondary antibody in 1% BSA in PBS with Ca2+ and Mg2+ was 
then added to each well, and incubated for 30 min at RT in an aluminum foil-covered box 
to prevent exposure to light. Wells were then washed once with 1% BSA in PBS with 
Ca2+ and Mg2+. The chambers were then removed from the slide, and one drop of 
Fluoroshield aqueous gel mountant containing 1 µg/mL 2-(4-amidinophenyl)-1H-indole-
6-carboxamidine (DAPI) was added to each well to stain the nuclei and mount the cover 
slip. DAPI was allowed to dry for 1 h at RT. Green fluorescence indicated CD26 
expression, which was visualized under a Zeiss LSM710 laser scanning confocal 
microscope, and images on this microscope were captured with Zen 2009 software.  
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3.9 High Performance Liquid Chromatography 
3.9.1 15d-PGJ2 Extraction  
 
 High performance liquid chromatography (HPLC) was used to determine the 
amount of remaining 15d-PGJ2 in culture medium at different time points after cell 
treatment. HT-29 cells were seeded in 6-well flat-bottomed plates at a density of 3 x 105 
cells and grown in DMEM with 10% NCS until approximately 70% confluent. 15d-PGJ2 
was added to each well for a defined amount of time (depending on the time course of the 
experiment), after which 500 µL of the media was withdrawn and collected in separate 2 
mL tubes. 500 µL of ice-cold methanol was added to each sample, and the samples were 
incubated in -20˚C for 10 min. The samples were then centrifuged at maximum speed for 
at 4˚C for 10 min. 1 mL chloroform/500 µL media was then added to each sample. The 
samples were vortexed for 30 s, and then centrifuged again at maximum speed for 10 min 
at 4˚C. ~1 mL of the bottom organic layer was carefully pipetted into a fresh 15 mL tube, 
and the chloroform was completely evaporated under a gentle nitrogen stream for 
approximately 3 h. The samples were then stored in -80˚C until further use. 
3.9.2 HPLC Method 
 
 Chromatography separations were performed using a 1200 series HPLC system 
(Agilent Technologies®) with a C-18 reverse phase column. The extracted 15d-PGJ2 
samples were dissolved in 20% methanol, and 25 µL of each sample was pipetted into a 
round-bottom 96-well polyethylene plate. The temperatures of the sample chamber and 
the column were 4˚C and 30˚C, respectively. The mobile phase consisted of 60% 
acetonitrile and 0.01% trifluoroacetic acid (TFA) (pH 3.5) with a flow rate of 1 mL/min. 
Each sample was passed through the column for 10 min, and UV absorption was detected 
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at 230 nm. The quantity of prostaglandin was based on electronic integration of the 
distinct 15d-PGJ2 peaks (i.e. calculating the area under the curve). A standard curve was 
generated to plot known concentrations against the prostaglandin peak area for 
determining unknown prostaglandin concentrations. The average retention time for 15d-
PGJ2 was 7.85 min. Three separate injections were taken per sample.  
3.10 Polymerase Chain Reaction 
3.10.1 mRNA Extraction 
 
HT-29 cells were seeded in a flat-bottomed 6-well plate in DMEM containing 
10% NCS at a density of 3 x 105 cells. Once grown to 70% of confluence, cells were 
treated with a particular prostaglandin for 24 h. Then, total mRNA was extracted from the 
cells using TRIzol® reagent. TRIzol dissolves DNA, RNA and protein. It contains 
guanidinium isothiocyanate that deactivates RNA-degrading enzymes, as well as acidic 
phenol that separates RNA into an aqueous supernatant. 1.25 mL of TRIzol® reagent was 
added to the cell monolayer to lyse the cells and incubated at RT for 5 min. 250 µL 
chloroform was added to each sample for phase separation and vortexed for 5 s, then 
incubated at RT for 5 min. The samples were then centrifuged at 12,000 x g at 4˚C for 15 
min which separated the contents into three phases: the bottom red organic phase 
containing protein, a middle white phase containing DNA, and the top colourless aqueous 
phase containing RNA. Approximately 600 µL of the colourless aqueous phase was 
carefully pipetted into a 2 mL tube. 3M potassium acetate (pH 5.2) and isopropanol were 
added to the sample at 10% and 70% of the volume of the aqueous phase, respectively. 
The samples were then incubated at RT for 10 min, and then centrifuged at 12,000 x g at 
4˚C for 20 min. The supernatant was discarded and 1 mL of 75% ethanol per 1 mL of 
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TRI® reagent was added to the samples to wash salts out of the RNA. The samples were 
centrifuged at 12,000 x g at 4˚C for 15 min. The supernatant was discarded and the 
resultant RNA pellet was air dried for 10 min. The pellet was dissolved in 50 µL of 
nuclease-free water, and the concentration of RNA was measured using a Nanodrop® 
2000c. The purity of the samples was discerned by the ratio of absorbance at 260 nm 
(wavelength of nucleic acid absorbance) to absorbance at 280 nm (wavelength of protein 
absorbance). A purity ratio of approximately 2 was acceptable. The mRNA samples were 
stored at -80˚C until further use. 
3.10.2 Reverse Transcription 
 
RNA samples were reverse transcribed into complementary DNA (cDNA) for 
PCR. Each reverse transcription  reaction started with 2.5 µg RNA and Master Mix 1. 
Master Mix 1 contained 0.5 µg/µL oligo dT and 10 mM dNTP in diethyl pyrocarbonate 
(DEPC) H2O. Oligo dTs served as primers for reverse transcriptase, dNTPs were the 
building blocks for cDNA synthesis, and DEPC H2O prevented RNA degradation by 
inactivating RNase enzymes. The samples were loaded into a Techne Genius Thermal 
Cycler and exposed to 65˚C for 5 min (oligo dT primer annealing stage), then were 
removed from the thermal cycler and chilled on ice for 15 s. 20 µL Master Mix 2 was 
added to each sample. Master Mix 2 contained a) 0.1 M DTT which loosened RNA 
structure and facilitated reverse transcriptase activity, b) RNase Out™ which prevented 
RNA degradation by ribonucleases, c) 200 U/µL M-MLV reverse transcriptase, and d) 
FS buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCL2; pH 8.3). The samples were 
loaded back into the thermal cycler and underwent the following program: 37˚C for 50 
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min (DNA polymerization), 70˚C for 15 min (reverse transcriptase deactivation), and 4˚C 
indefinitely (holding stage).   
3.10.3 End Point PCR and Gel Electrophoresis 
 
End point PCR was performed to amplify cDNA samples for visualization. Each 
reaction contained 2.5 µg cDNA, 12.5 µL GoTaq® Green, 0.5 µL forward primer, 0.5 µL 
reverse primer, and 9.5 µL Milli Q H2O. PCR was performed using a thermal cycler, 
which underwent 36 cycles of the following program: 94ºC for 110 s (denaturing), 60ºC 
for 45 s (annealing), 72ºC for 60s (extension), and 72ºC for 10 min (final extension). 5 
µL of PCR samples were loaded into the wells of a 1% agarose gel. Electrophoresis was 
run at 95 V for approximately 30 min. Images of the gel were captured under UV light 
using an Alpha Imager® HP machine (Alpha Innotech - MultiImage®II). 
3.10.4 Quantitative Real-Time PCR 
 
 Quantitative PCR was used to quantify mRNA expression of DPPIV/CD26. First, 
cDNA concentration was diluted to 5 ng/µL in DEPC distilled water. qPCR reactions 
were performed in a low profile semi-skirted 96-well PCR plate. Each qPCR reaction 
contained 25 ng cDNA, 200 nM forward primer, 200 nM reverse primer, and 10 µL SSO 
Advanced SYBR Green qPCR Mix. qPCR was performed using a StepOnePlus™ Real-
Time PCR System under the following thermal conditions: 95˚C for 30 s (polymerase 
activation), 95˚C for 15 s (denaturation), and 60˚C for 60 s (annealing and extension) for 
40 cycles. The ΔΔCq relative quantification method was used to determine the fold 
change in gene expression. The software LinRegPCR® was used to analyze the 
fluorescence data and produce a quantification cycle (Cq) value for each sample. The Cq 
value represents the number of cycles needed to reach the fluorescence threshold. Cq 
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values were used to calculate the N0 value of each sample. The N0 value indicates the 
starting concentration of the target gene and is expressed in arbitrary fluorescence units. 
N0 values of CD26 were normalized to GAPDH N0 values. 
3.11 Cell Migration Assay 
 
 A cell migration assay was used to investigate changes in cellular interactions 
with the ECM. General cancer cell migration was measured using HT-29 cells, and 
normal stromal tissue wound healing/remodeling was measured using NIH3T3 cells. HT-
29 and NIH3T3 cells were separately seeded in flat-bottomed 6-well plates in DMEM 
containing 10% NCS at a density of 3 x 105 cells. At approximately 80% confluence, the 
cells were treated with the vehicle control, or different concentrations of 15d-PGJ2, for 48 
h. Then, two vertical parallel scratches were etched into the monolayer using a P1000 
pipette tip. The media was aspirated, and the wells were washed once with DMEM 
containing 20% FBS. 3 mL of DMEM containing 20% FBS was then added to each well 
to stimulate cell migration. Reference markings on the bottom of each well were etched 
with a thin sharp needle. The scratches, or wounds, were observed under a Leica 
DM2000 light microscope, and images on this microscope were captured using a 
Micropublisher 5.0 RTV camera with QCapture Pro 5 software. Images of each scratch 
wound were captured immediately after the wounds were created, and afterwards at 24 h 
intervals or less according to the pace of wound healing. ImageJ software was used to 
calculate the area of each scratch wound at different time intervals.  
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3.12 Analysis and Statistics 
 
 GraphPad Prism 7 software was used for data analysis. ImageJ® was used for 
quantitation of intensity of images in end-point PCR and Western blotting. Analysis of 
variance (ANOVA) was performed to analyze statistically significant differences in cell 
response. A one-way ANOVA was followed by Dunnett’s multiple comparisons test, and 
a 2-way ANOVA was followed by Bonferroni’s multiple comparisons test. P<0.05 was 
chosen as the threshold for statistically significant differences. Analyzed data were either 
triplicate wells of one experiment, or means from at least three independent experimental 
replicates. For non-quantitative results, figures that were most representative of all 
experimental findings were selected for inclusion. 
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4. Results 
In this project I measured the expression of DPPIV/CD26 and its dipeptidase 
activity on HT-29 colon carcinoma cells after prostaglandin treatment. I then explored the 
effect of prostaglandins on nondirectional cell migration. I investigated PGD2 and its J-
series derivatives PGJ2 and 15d-PGJ2, and used PGF2α as a non-J-series prostaglandin for 
comparison.  
4.1 Measuring changes in DPPIV/CD26 dipeptidase activity after prostaglandin 
treatment 
I first investigated whether each of these prostaglandins altered the level of 
DPPIV/CD26 dipeptidase activity on colon carcinoma cells. Cultured cells were treated 
with different concentrations of one prostaglandin for 48 h. DPPIV/CD26 enzyme 
activity was quantified by spectrophotometrically measuring pNA release from the 
DPPIV substrate Gly-Pro-pNA. Results showed that PGD2 decreased DPPIV/CD26 
activity by 26% on HT-29 cells (Figure 4.1 A), but had no significant effect on Caco-2 
cells (Figure 4.1 B). The J-series prostaglandins showed to significantly decrease 
DPPIV/CD26 dipeptidase activity at the highest concentrations on both HT-29 cells and 
Caco-2 cells. PGJ2 decreased DPPIV/CD26 activity by 73% on HT-29 cells (Figure 4.2 
A), and by 77% on Caco-2 cells (Figure 4.2 B). The highest concentration of 15d-PGJ2 
treatment showed to reduce DPPIV/CD26 activity by 86% on HT-29 cells (Figure 4.3 A) 
and by 80% on Caco-2 cells (Figure 4.3 B). PGF2α slightly increased DPPIV/CD26 
enzyme activity by up to 9% in a concentration-dependent manner beginning at 10 µM 
(Figure 4.4).  
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Figure 4.1: Concentration-dependent effect of PGD2 on DPPIV dipeptidase activity 	  
 
HT-29 cells (A) and Caco-2 cells (B) were treated with PGD2 at the indicated 
concentrations for 48 h. DPPIV/CD26 peptidase activity was quantified by the 
absorbance of p-nitroanilide at 405 nm. Percent Maximum Absorbance was calculated by 
subtracting the absorbance of blank control samples from the absorbance of experimental 
samples, divided by the average absorbance of control-treated experimental samples. 
Data of each graph are means ± standard error of the mean (SEM) from triplicate wells of 
one independent experiment. Data were analyzed by a one-way ANOVA with Dunnett’s 
multiple comparisons test. ****P<0.0001 shows a significant difference in DPPIV 
activity between the control treatment and PGD2 treatment. 
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Figure 4.2: Concentration-dependent effect of PGJ2 on DPPIV dipeptidase activity 	  
 
HT-29 cells (A) and Caco-2 cells (B) were treated with PGJ2 at the indicated 
concentrations for 48 h. DPPIV/CD26 peptidase activity was quantified by the 
absorbance of p-nitroanilide at 405 nm. Percent Maximum Absorbance was calculated by 
subtracting the absorbance of blank control samples from the absorbance of experimental 
samples, divided by the average absorbance of control-treated experimental samples. The 
data are means ± SEM. Graph A shows data from three independent experiments; Graph 
B shows data from one independent experiment. Data were analyzed by a one-way 
ANOVA with Dunnett’s multiple comparisons test. *P<0.05, **P<0.01 and 
****P<0.0001 show a significant decrease in DPPIV activity between the control 
treatment and PGJ2 treatment. 
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Figure 4.3: Concentration-dependent effect of 15d-PGJ2 on DPPIV activity	  
 
HT-29 cells (A) and Caco-2 cells (B) were treated with 15d-PGJ2 for 48 h at the indicated 
concentrations. DPPIV/CD26 peptidase activity was quantified as the absorbance of p-
nitroanilide at 405 nm. Percent Maximum Absorbance was calculated by subtracting the 
absorbance of blank control samples from the absorbance of experimental samples, 
divided by the average absorbance of control-treated experimental samples. The data are 
means ± SEM. Graph A represents three independent experiments; Graph B represents 
four independent experiments. Data were analyzed by a one-way ANOVA with 
Dunnett’s multiple comparisons test. *P<0.05 shows a significant difference in DPPIV 
activity between the control treatment and 15d-PGJ2 treatment. 
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Figure 4.4: Concentration-dependent effect of PGF2α on DPPIV dipeptidase activity	  
 
Caco-2 cells were treated with PGF2α at the indicated concentrations for 48 h. 
DPPIV/CD26 peptidase activity was quantified by the absorbance of p-nitroanilide at 405 
nm. Percent Maximum Absorbance was calculated by subtracting the absorbance of 
blank control samples from the absorbance of experimental samples, divided by the 
average absorbance of control-treated experimental samples. Data are means ± SEM from 
three independent experiments. Data were analyzed by a one-way ANOVA with 
Dunnett’s multiple comparisons test. **P<0.01 shows a significant increase in DPPIV 
activity between the control treatment and PGF2α treatment. 
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Through the course of performing DPPIV/CD26 enzymatic activity assays I noticed 
that the absolute magnitude of the response sometimes varied between independent 
experiments. Realizing that cultures might be at different stages of growth, I decided to 
investigate whether cell confluency at the time of prostaglandin treatment affected cell 
response. Cell confluency is the proportion of a culture flask that is covered by adherent 
cells. HT-29 cells were grown to either 60% or 90% of confluence, and then treated with 
different concentrations of 15d-PGJ2 or PGF2α for 48 h. Results showed that cell 
confluency indeed influenced the effect of both prostaglandins on DPPIV/CD26 enzyme 
activity. At the highest concentration of 15d-PGJ2, cells that were 60% confluent at the 
time of treatment exhibited a more substantial decrease (91%) in DPPIV/CD26 activity 
than 90% confluent cells (41%) (Figure 4.5 A). PGF2α did not appear to change 
DPPIV/CD26 activity on 60 percent confluent cells, yet induced a slight concentration-
dependent increase (3%) in DPPIV/CD26 activity on 90% confluent cells starting at 10 
µM (Figure 4.5 B). Since the magnitude of cell response changed with cell confluency, I 
controlled for cell confluency at the time of prostaglandin treatment for all future 
experiments. 
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Figure 4.5: The effects of cell confluence on prostaglandin-induced changes in 
DPPIV/CD26 activity	  
 
Caco-2 cells were grown to 60 percent confluence or 90 percent confluence, and treated 
with 15d-PGJ2 (A) or PGF2α (B) for 48 h at the indicated concentrations. DPPIV 
peptidase activity was quantified by the absorbance of p-nitroanilide at 405 nm. Percent 
Maximum Absorbance was calculated by subtracting the absorbance of blank control 
samples from the absorbance of experimental samples, divided by the average absorbance 
of control-treated experimental samples. The data in each graph are means ± SEM from 
one independent experiment. Data were analyzed by a two-way ANOVA – which 
indicated a significant interaction between the two levels of cell confluence – followed by 
a Bonferroni multiple comparisons test. *P<0.05, **P<0.01, ***P<0.001 and 
****P<0.0001 indicate significant differences between control treatment and 
prostaglandin treatment at one confluence percentage. 
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4.2 Measuring the potential toxicity of prostaglandins on HT-29 cells 
4.2.1 Measuring prostaglandin cytotoxicity using an MTT assay 
 
 In the investigations shown above, PGJ2 and 15d-PGJ2 both appeared to reduce 
DPPIV/CD26 dipeptidase activity at high concentrations. Previous studies have shown 
that similar or lower concentrations of J-series prostaglandins can induce cancer cell 
death (Clay et al., 1999; Yen et al., 2014). Thus, the apparent decrease in DPPIV/CD26 
enzyme activity may have actually resulted from a decrease in the number of viable cells, 
reducing the amount of functional DPPIV/CD26 to be measured. To investigate the 
potential cytotoxicity of each prostaglandin, I first employed an MTT assay. The MTT 
assay estimates the viability of cells by quantifying their mitochondrial activity. Caco-2 
and HT-29 cells were exposed to a prostaglandin at the same concentrations used in the 
DPPIV activity assays for the same amount of time (48 h). The prostaglandins did not 
significantly decrease cell viability according to the MTT assay at any concentration over 
the course of my experiments (Figure 4.6), despite some individual experimental 
replicates suggesting a decrease that was not statistically significant.   
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Figure 4.6: Cell viability after prostaglandin treatment measured by an MTT assay	  
 
HT-29 cells were treated with PGD2 (A), PGJ2 (B), 15d-PGJ2 (C) or PGF2α (D) for 48 h 
at the indicated concentrations. Cell viability was measured using an MTT assay. Percent 
Maximum Absorbance was calculated by subtracting the absorbance of blank control 
samples from the absorbance of experimental samples, divided by the average absorbance 
of control-treated experimental samples. The data are means ± SEM. Graphs A represents 
four independent experiments, Graphs B and D each represent three independent 
experiments, and Graph C represents five independent experiments. Data were analyzed 
by a one-way ANOVA with Dunnett’s multiple comparisons test. No significant 
difference was found between the control treatment and any prostaglandin treatment. 
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4.2.2 Measuring prostaglandin cytotoxicity by counting viable cells 
 
 To confirm the MTT results that reflect an indirect approach, I directly counted 
the number of viable cells after prostaglandin treatment. HT-29 cells were exposed to 
different concentrations of the prostaglandin for 48 h. Intact, full-sized (and therefore 
presumed viable) cells were then counted using a digital multisizer. Results showed that 
PGD2 and PGJ2 both significantly reduced the number of viable cells at high 
concentrations by up to 38% (P<0.001) and 99% (P<0.0001), respectively (Figure 4.7 A; 
Figure 4.7 B). Furthermore, 15d-PGJ2 significantly decreased cell viability at the highest 
concentration by 88% (P<0.05) (Figure 4.7 C). PGF2α had a very little effect on cell 
viability, producing a small (11%) reduction at the highest concentration (Figure 4.7 D).  
These cell count results contradicted the MTT results which showed that PGD2, PGJ2 and 
15d-PGJ2 did not significantly alter HT-29 cell viability. This casts doubt on the 
reliability of the MTT assay. Since counting viable cells is a more direct measure of 
prostaglandin cytotoxicity than using an MTT assay, I concluded that the J-series 
prostaglandins and their parent compound PGD2 were indeed cytotoxic to HT-29 cells at 
the highest concentrations.  
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Figure 4.7: Mean percent viable cell count after prostaglandin treatment	  
 
HT-29 cells were treated with PGD2 (A), PGJ2 (B), 15d-PGJ2 (C) or PGF2α (D) for 48 h 
at the indicated concentrations. Viable cell count was measured using a digital multisizer. 
The data for Graphs A, B and D are means ± SEM of triplicate wells, each from one 
independent experiment. The data for Graph C are means ± SEM from seven independent 
experiments. Data were analyzed by a one-way ANOVA with Dunnett’s multiple 
comparisons test. *P<0.05, ***P<0.001, and ****P<0.0001 indicate a significant 
difference between the vehicle control and prostaglandin treatment.  
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4.3 Measuring DPPIV/CD26 dipeptidase activity after prostaglandin treatment 
while controlling for cytotoxic effects 
Since the cell counting results showed that PGJ2 and 15d-PGJ2 both decreased the 
number of viable HT-29 cells, I decided to measure DPPIV/CD26 dipeptidase activity 
while controlling for prostaglandin cytotoxicity; i.e. to study the activity normalized to 
per viable cell. HT-29 cells were exposed to different concentrations of a prostaglandin 
for 48 h as before. For each experiment, half of the cultures were measured for 
DPPIV/CD26 dipeptidase activity, while cells in the parallel cultures were counted. 
DPPIV/CD26 enzyme activity was then normalized to the number of viable cells. As 
expected, PGD2 did not alter the level of DPPIV/CD26 dipeptidase activity on viable 
cells (Figure 4.8 A). The increases in mean DPPIV/CD26 activity after PGJ2 (150%) and 
15d-PGJ2 (93%) treatments were not statistically significant; these results exhibited much 
higher variability between experimental replicates (Figure 4.8 B; Figure 4.8 C). 
Interestingly, PGF2α slightly increased DPPIV/CD26 activity at the lowest concentration 
by 21% and this increase was statistically significant (Figure 4.8 D). These findings 
contradicted my initial results on DPPIV/CD26 activity, which showed a decline after 
PGJ2 and 15d-PGJ2 treatments without controlling for cell death (Figure 4.2; Figure 4.3).  
 In this series of experiments I noticed that the magnitude of responses differed 
between experimental replicates. It seemed possible that culture growth parameters 
contributed to variations in cell response, in addition to the confluence level studied 
earlier. For practical reasons to do with cell culture, cells used in some replicates of the 
DPPIV/CD26 enzymatic assay had been grown in DMEM supplemented with 10% NCS, 
whereas others were grown in DMEM supplemented with 5% FBS. NCS differs from 
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FBS in that it contains less growth factors and higher total protein levels. The type of 
serum has shown to affect cancer cell morphology and the rate of cell proliferation, 
which in return can lead to alterations in cell response (Fang, Wu, Fang, Chen, & Chen, 
2017). However, when comparing DPPIV/CD26 dipeptidase activity on HT-29 cells 
grown in NCS vs. FBS, there was no significant interaction between serum type and 15d-
PGJ2 concentration (Figure 4.9). Therefore, the type of culture serum did not affect 
DPPIV/CD26 enzyme activity in response to 15d-PGJ2. Another difference between 
experimental replicates was the rate of cell growth. After seeding HT-29 cells in 24-well 
plates for DPPIV/CD26 enzyme activity assays at the same density, they grew slowly 
during some experiments (i.e. seven days to reach 60 percent confluence), and during 
others they grew quickly (i.e. three days to reach 60 percent confluence). I decided to 
investigate whether the rate of HT-29 cell growth indicated changes in cell response to 
15d-PGJ2 by comparing DPPIV/CD26 enzyme activity between slow-growing cells and 
fast-growing cells. There was no statistically significant interaction between the pace of 
cell growth and 15d-PGJ2 concentration (Figure 4.10). It is likely that there are many 
factors related to cell culture that contribute to experimental variability. 
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Figure 4.8: DPPIV/CD26 dipeptidase activity normalized to viable cell count after 
prostaglandin treatment	  
 
HT-29 were treated with PGD2 (A), PGJ2 (B), 15d-PGJ2 (C), or PGF2α (D) for 48 h at the 
indicated concentrations. DPPIV peptidase activity was quantified as the absorbance of p-
nitroanilide at 405 nm. Viable cells were counted using a digital multisizer. DPPIV 
Activity was calculated by taking the absorbance over time, divided by the average 
number of cells counted. The data for Graphs A and D are means ± SEM of triplicate 
wells, each from one independent experiment. The data for Graph C are means ± SEM 
from three independent experiments, and the data for Graph B are means ± SEM from 
eight independent experiments. Data were analyzed by a one-way ANOVA with 
Dunnett’s multiple comparisons test. *P<0.05 shows a significant difference between the 
control treatment and PGF2α treatment. 
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Figure 4.9: Lack of effect of cell culture serum on 15d-PGJ2-induced changes in 
DPPIV/CD26 dipeptidase activity	  
 
HT-29 cells were grown in DMEM supplemented with either 10% NCS or 5% FBS, and 
then treated with 15d-PGJ2 for 48 h at the indicated concentrations. DPPIV/CD26 
dipeptidase activity was quantified as the absorbance of p-nitroanilide at 405 nm. Viable 
cells were counted using a digital multisizer. DPPIV Activity was calculated by taking 
the absorbance over time, divided by the average number of cells counted. The 10% NCS 
data are means ± SEM from five independent experiments. The 5% FBS data are means ± 
SEM from three independent experiments. Data were analyzed by a two-way ANOVA 
with a Bonferroni multiple comparisons test. No significant interaction was found 
between the type of serum and 15d-PGJ2 concentration. 
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Figure 4.10: Lack of effect of pace of cell growth on 15d-PGJ2-induced changes in 
DPPIV/CD26 dipeptidase activity	  
 
HT-29 cells were seeded and grown to 60 percent confluence, which either took 
approximately seven days (slow-growing) or three days (fast-growing). They were then 
treated with 15d-PGJ2 for 48 h at the indicated concentrations. DPPIV/CD26 dipeptidase 
activity was quantified as the absorbance of p-nitroanilide at 405 nm. Viable cells were 
counted using a digital multisizer. DPPIV Activity was calculated by taking the 
absorbance over time, divided by the average number of cells counted. The slow-growing 
data are means ± SEM from two independent experiments. The fast-growing data are 
means ± SEM from six independent experiments. Data were analyzed by a two-way 
ANOVA with a Bonferroni multiple comparisons test. No significant interaction was 
found between the pace of cell growth and 15d-PGJ2 concentration. 
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4.4 Characterizing changes in DPPIV/CD26 mRNA expression in response to 
prostaglandin treatment 
 Given the uncertainty of my findings about the level of DPPIV/CD26 enzyme 
activity after exposure to different prostaglandins, I decided to quantify the expression 
and abundance of DPPIV/CD26 at the mRNA and protein level. I first investigated 
DPPIV/CD26 mRNA expression in HT-29 cells after 24 to 36 h prostaglandin treatment 
via end-point PCR with agarose gel analysis (Figure 4.11). The J-series prostaglandins 
PGD2 (Figure 4.11 A) and PGJ2 (Figure 4.11 B), and the structurally distinct PGF2α 
(Figure 4.11 D), showed no evidence for a dose-dependent increase in DPPIV/CD26 
mRNA expression either visually or on ImageJ® analysis of band intensity (not shown). 
However, 15d-PGJ2 showed evidence of a slight increase in DPPIV/CD26 mRNA 
expression at the highest treatment dose of 40 µM when independent experiments were 
analyzed using Image J® (mean increase 12.0%, n=3 experiments, P<0.05).  
I sought to extend these results using DPPIV/CD26 expression after using qPCR, 
which is much more sensitive to changes in expression than end point PCR. Interestingly, 
these qPCR results – normalized to GAPDH to control for cytotoxicity – revealed a 
substantial and significant concentration-dependent decline in DPPIV/CD26 mRNA 
abundance by up to 85% at higher concentrations of 15d-PGJ2 (Figure 4.12).  
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Figure 4.11: DPPIV/CD26 mRNA expression after prostaglandin treatment	  
HT-29 cells were treated with either PGD2 (A), PGJ2 (B), 15d-PGJ2 (C) or PGF2α (D) at 
the indicated concentrations for 24 to 36 h. mRNA was extracted, reverse transcribed to 
cDNA, and amplified via PCR. Images were taken on an Alpha Imager® HP machine. 
GAPDH expression was used as a positive control compared to CD26 expression. Images 
A and B show single independent experiments; Image C is representative of three 
independent experiments; Image D is representative of two independent experiments. 
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Figure 4.12: DPPIV/CD26 mRNA expression in HT-29 cells after 15d-PGJ2 
treatment 
 
HT-29 cells were treated with 15d-PGJ2 at the indicated concentrations for 24 h. mRNA 
was extracted, reverse transcribed to cDNA, and amplified and quantified via qPCR. 
GAPDH expression was used as a positive control. mRNA expression was expressed in 
arbitrary fluorescence units. Percent Maximum DPPIV/CD26 mRNA Abundance was 
calculated as the ratio of CD26 mRNA fluorescence to the mean GAPDH mRNA 
fluorescence, and this ratio was then normalized to that at 0 µM 15d-PGJ2. The data 
represent means ± SEM from three independent experiments. Data were analyzed by a 
one-way ANOVA with Dunnett’s multiple comparisons test. **P<0.01 shows a 
significant decrease in CD26 mRNA expression between the vehicle control and 15d-
PGJ2 treatment. 
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4.5 Characterizing changes in DPPIV/CD26 whole cell protein expression in 
response to prostaglandin treatment 
 The qPCR results showed that 15d-PGJ2 induced a concentration-dependent 
decrease in DPPIV/CD26 mRNA expression. Oftentimes changes in the transcription of a 
gene are not reflected in alterations emerging after protein translation (Vogel & Marcotte, 
2012). I investigated whether the decrease in DPPIV/CD26 mRNA expression was 
reflected at the protein level. HT-29 cells were dosed with either the vehicle control or 
different concentrations of one prostaglandin, and whole-cell DPPIV/CD26 protein 
expression was visualized by Western blotting. Results showed that there was no 
consistent shift in whole-cell DPPIV/CD26 protein expression after PGD2, PGJ2 or 15d-
PGJ2 treatments (Figure 4.13). Analysis of band intensity using ImageJ® software 
confirmed that in spite of variations in measured intensity of up to 20% from the mean in 
certain lanes, there was no consistent change in protein expression (P value for test of 
change in DPPIV/CD26 protein expression at the highest treatment dose of 40 µM of 
15d-PGJ2 > 0.35, n=3 independent experiments). Therefore, the apparent decline in 
DPPIV/CD26 mRNA expression after 15d-PGJ2 exposure (as measured by qPCR) was 
not paralleled by a decrease in DPPIV/CD26 whole-cell protein abundance. Furthermore, 
the possible increase in DPPIV dipeptidase activity at high concentrations of PGJ2 and 
15d-PGJ2 suggested by the averaged data could not be related to an increase in 
DPPIV/CD26 protein. The possible changes in both mRNA and DPPIV enzyme activity 
are therefore not supported by evidence for a change in whole-cell protein. 
 
 
	   70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Whole-cell DPPIV/CD26 protein expression after 24 h prostaglandin 
treatment	  
 
HT-29 cells were treated with either PGD2 (A), PGJ2 (B), or 15d-PGJ2 (C, D) at the 
indicated concentrations for 24 h. Protein samples were extracted, separated by SDS-
PAGE, blotted to a PVDF membrane, and probed for CD26. Images were captured using 
a Kodak™ Image Station 4000 mm Pro. Image A is representative of two independent 
experiments; Image B shows the outcome of one independent experiment; Image C is 
representative of three independent experiments. Image D depicts 15d-PGJ2-treated 
protein samples probed for β-actin as a positive control to confirm uniform protein 
loading. 
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4.6 Characterizing the localization of DPPIV/CD26 protein expression on HT-29 
cells in response to prostaglandin treatment 
Since the prostaglandins did not change the abundance of DPPIV/CD26 protein 
within the whole cell as shown by the Western blot results, I decided to investigate 
whether they instead altered the display of functional DPPIV/CD26 protein at the cell 
surface. Increased cell-surface DPPIV/CD26 protein expression may have resulted in a 
potential increase in DPPIV/CD26 dipeptidase activity that was suggested in some of my 
experiments. I used immunofluorescence staining to visualize cell-surface DPPIV/CD26 
expression after 48 h treatment with the prostaglandins at different concentrations. 
DPPIV/CD26 was abundantly expressed on the cell surface as indicated by the high level 
of fluorescence intensity, however the surface localization of immunoreactive 
DPPIV/CD26 did not change with treatment of PGF2α, PGD2, PGJ2 or 15d-PGJ2 at any 
concentration (Figure 4.14). Therefore, J-series prostaglandins did not change cell-
surface DPPIV/CD26 protein expression.  
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Figure 4.14: Cell-surface DPPIV/CD26 expression after prostaglandin treatment	  
 
HT-29 cells were treated with either PGF2α, PGD2, PGJ2 or 15d-PGJ2 at the indicated 
concentrations for 48 h. Cells were then fixed onto a chamber slide with 1% 
paraformaldehyde, and fluorescently probed for cell-surface CD26. Images were taken on 
a Zeiss® LSM710 laser scanning confocal microscope by Roger Chen from the laboratory 
of Dr. Marianna Foldvari. This figure represents the results of two independent 
experiments.  
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4.7 Measuring the effect of 15d-PGJ2 on cell migration on the extracellular matrix  
 Results thus far suggested that prostaglandin treatment did not significantly 
impact DPPIV/CD26 expression and dipeptidase activity on HT-29 cells. Nevertheless, to 
be sure there was no consistent response to 15d-PGJ2 I decided to measure another aspect 
of DPPIV/CD26 activity, which was cell migration over the ECM. I characterized cell 
migration by measuring the rate of non-directed cell movement across an area that had 
been first cleared of cells but has ECM that was already produced by those cells; this 
technique is usually known as a wound-healing assay. I used HT-29 cells to mimic cancer 
cell migration at the tumour invasive front, and NIH3T3 cells to mimic the healing of 
wounds by normal cells, or fibrous remodelling. Results appeared to show that the 
highest concentration of 15d-PGJ2 significantly decreased the rate of both HT-29 and 
NIH3T3 cell migration by 79% and 17%, respectively (Figure 4.15). However, it is 
important to note that when observed under a light microscope at different time points, 
HT-29 cells were proliferating more quickly than usual, and some cells appeared to be 
dead due to their morphology. This may have indicated that the area of the wound 
decreased due to accelerated HT-29 cell proliferation, rather than gradual migration 
across the wound (Figure 4.16). On the other hand, NIH3T3 cells appeared to be 
migrating toward the wound, due to their gradual dispersion and lack of cell death 
(Figure 4.17). 
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Figure 4.15: The rate of HT-29 and NIH3T3 cell migration in response to 15d-PGJ2 
treatment	  
 
HT-29 (A) and NIH3T3 (B) cells were treated with 15d-PGJ2 at the indicated 
concentrations for 48 h, after which a wound was made in which cells were removed 
from the monolayer in a vertical line. The area of the wound was measured at 0 h and 36 
h. The rate of cell migration was calculated as the percent of the wound covered by cells 
over the time after the wound was made. The data represent means ± SEM from one 
independent experiment performed in triplicate. Data were analyzed by a one-way 
ANOVA with Dunnett’s multiple comparisons test. **P<0.01 shows a significant 
decrease between the vehicle control and prostaglandin treatment. 
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Figure 4.16: Wound healing by HT-29 cells at different 15d-PGJ2 concentrations 
over time	  
  
HT-29 cells were treated with 15d-PGJ2 at the indicated concentrations for 48 h, after 
which a wound was made where cells were removed from the monolayer in a vertical 
line. The area of the wound was measured at 0 h and 36 h. Cells were observed under a 
Leica DM2000 light microscope, and images on this microscope were captured using a 
Micropublisher 5.0 RTV camera with QCapture Pro 5 software by Judah Glogauer (0 h) 
and myself (36 h). These images are representative of one experiment. 
0 µM 
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Figure 4.17: Wound healing by NIH3T3 cells at different 15d-PGJ2 concentrations 
over time	  
  
NIH3T3 cells were treated with 15d-PGJ2 at the indicated concentrations for 48 h, after 
which a wound was made where cells were removed from the monolayer in a vertical 
line. The area of the wound was measured at 0 h and 36 h. Cells were observed under a 
Leica DM2000 light microscope, and images on this microscope were captured using a 
Micropublisher 5.0 RTV camera with QCapture Pro 5 software by Judah Glogauer (0 h) 
and myself (36 h). These images are representative of one experiment. 
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4.7 Quantifying the abundance of 15d-PGJ2 treatment in cell culture medium over 
time using high-performance liquid chromatography 
 Results thus far showed substantial conflicts and variability in my results for (i) 
DPPIV/CD26 dipeptidase activity, (ii) DPPIV/CD26 mRNA expression, and (iii) 
DPPIV/CD26 expression at the protein level. This was not obviously due to technical 
issues, and was seen both within experiments and between experimental replicates. I 
therefore sought to confirm whether the J-series prostaglandins were consistently 
available during treatment to produce a cell response in a predictable and concentration-
dependent manner. Prostaglandins, and eicosanoids in general, have short half-lives 
ranging from seconds to minutes, and thus may break down before they can induce a 
consistent cell response (Folco & Murphy, 2006; Funk, 2001). I used HPLC to identify 
the amount of 15d-PGJ2 in cell culture media from HT-29 cell cultures at different time 
points after treatment. Results showed that most of the added 15d-PGJ2 was still present 
in the media 30 min after treatment at the lower concentrations that were used in my 
studies (Figure 4.18; Figure 4.19). However, intriguingly at the highest concentration, 
there was an enhanced breakdown of 15d-PGJ2 (Figure 4.18; Figure 4.19). The level of 
15d-PGJ2 substantially declined by 38% 5 min after treatment, and significantly declined 
by 82% 30 min after treatment. This dramatic breakdown of 15d-PGJ2 at only the highest 
concentration may indicate a shift in cellular metabolism that affects cell regulation due 
to this eicosanoid, and may be a further complicating factor in defining the cellular 
responses that may occur in response to J-series prostaglandins. 
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Figure 4.18: The amount of 15d-PGJ2 treatment remaining in cell culture media 
over time at different initial concentrations	  
 
HT-29 cells were treated with 15d-PGJ2 at the indicated concentrations. 15d-PGJ2 was 
then extracted from the media at the indicated time points. The amount of extracted 15d-
PGJ2 was quantified using HPLC. The data are means ± SEM of triplicate wells, from 
one independent experiment. Data were analyzed by a two-way ANOVA with a 
Bonferroni multiple comparisons test. **P<0.01 indicates a significant decrease in 15d-
PGJ2 between 0 min and another time point. 
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Figure 4.19: Chromatograms of 15d-PGJ2 detection by HPLC over time	  
 
HT-29 cells were treated with 15d-PGJ2 at 30 µM (A) and 60 µM (B), which was then 
extracted from the media 0 min, 5 min and 30 min after treatment. The amount of 
extracted 15d-PGJ2 was quantified using HPLC. The X-axis represents the retention time 
in minutes, and the Y-axis represents the intensity of absorbance at 230 nm in milli-
Absorbance Units (mAU). The area under each curve is proportional to the amount of 
15d-PGJ2 remaining at that time. The image is representative of three independent 
experiments. 
 
 
 
 
 
 
A) 
B) 
	   80 
5. Discussion 
 Dipeptidyl peptidase IV/CD26 on the surface of cancer cells exerts several anti-
metastatic functions, and shows variable expression in cancer that may relate to the 
tendency to metastasize. In this project I studied the effect of prostaglandins, primarily of 
the J-series, on DPPIV/CD26 expression and activity on human colon adenocarcinoma 
cells. I mainly examined HT-29 cells, which sufficiently express DPPIV/CD26, and 
reproduced some findings using Caco-2 cells. Both cell lines can form differentiated 
epithelia, and therefore can be used to model the intestinal epithelium (Darmoul et al., 
1991; Howell, Kenny, & Turner, 1992). 
 I investigated four prostaglandins – three that are sequential products in the J-
structural series (PGD2, PGJ2 and 15d-PGJ2), and another (PGF2α) that provides a 
different structural example. The J-series prostaglandins are present in the colonic tumour 
microenvironment: PGD2 has been studied by other groups (Boughton-Smith et al., 1983; 
Fajas et al., 1997) and 15d-PGJ2 has been measured in tumour xenografts by 
microdialysis (Blay et al., unpublished; Blay, White & Hoskin, 1997).  Previous work in 
the Blay laboratory has shown that J-series prostaglandins decrease CXCR4 expression 
on HT-29 cells (Richard, Lowthers & Blay, 2007). As discussed earlier, CXCR4 and 
DPPIV/CD26 are likely regulated in parallel and usually in opposite directions. Thus, I 
investigated whether the J-series prostaglandins would induce an increase in 
DPPIV/CD26 expression and activity on HT-29 colon carcinoma cells.  
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5.1 Prostaglandins initially appeared to downregulate DPPIV/CD26 dipeptidase 
activity 
Dipeptidyl peptidase IV/CD26 may suppress metastasis through its dipeptidase 
activity. DPPIV cleaves and thus inactivates the pro-tumorigenic chemokine CXCL12 
(Sun et al., 2008). I first measured DPPIV dipeptidase activity in response to 
prostaglandin treatment. Initially PGD2, PGJ2 and 15d-PGJ2 appeared to decrease DPPIV 
activity; this contradicted my hypothesis that J-series prostaglandins would instead 
increase DPPIV activity. However, these data showed high variability, and suggested the 
occurrence of cell death at high prostaglandin concentrations. 
5.2 The apparent decrease in DPPIV/CD26 dipeptidase activity reflected cell death 
after prostaglandin treatment 
To investigate possible cell death, an MTT assay was first employed. In this 
assay, the tetrazolium salt MTT penetrates viable cells, and is reduced to formazan by 
NAD(P)H-dependent enzymes in the mitochondria (Riss et al., 2004). Cell viability is 
quantified by the amount of formazan produced. The MTT assay showed no significant 
decrease in cell viability after prostaglandin treatment. However, a subsequent cell 
counting assay revealed a significant decrease in cell viability at high concentrations of 
PGD2, PGJ2, and 15d-PGJ2.  
There was a remarkable discrepancy between the cytotoxicity shown by the actual 
number of viable cells and that estimated by the MTT assay. This is likely due to 
differences in the way that each assay measures cell viability. While cell counting 
directly quantifies viable cells, an MTT assay estimates those cells indirectly by 
measuring their mitochondrial activity. But if the compound of interest alters 
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mitochondrial activity in any way, cell viability can be misjudged. For example, Pagliacci 
et al. (1993) found that the MTT assay consistently overestimated the number of viable 
breast cancer and leukemia cells remaining after treatment with the plant flavonoid 
genistein. The authors discovered that genistein increased mitochondrial activity in these 
cells, thereby increasing formazan production and overestimating cell viability. A direct 
count of viable cells revealed a dramatic decrease in cell number. Counting viable cells 
was a more valid measure of genistein cytotoxicity than the MTT assay for these authors 
and in my own study.  
PGD2, PGJ2 and 15d-PGJ2 significantly decreased HT-29 colon cancer cell 
survival at high concentrations. These results agree with previous findings by others on 
prostaglandin cytotoxicity. J-series prostaglandins have been shown to induce cytotoxic 
effects in various cancer cell lines. In leukemia cells, PGJ2 and its metabolite, Δ12-PGJ2, 
induced apoptosis (Y. C. Chen, Shen, & Tsai, 2005; I. K. Kim et al., 1993). Δ12-PGJ2 is 
also cytotoxic to osteosarcoma, melanoma, ovarian, prostate, colon, pancreas, small cell 
lung cancer, and breast cancer cell lines (McClay, Winski, Jones, Jennerette, & Gattoni-
Celli, 1996; T. Sakai et al., 1989). The final PGJ2 metabolite, 15d-PGJ2, has been 
extensively studied for its ability to induce apoptosis, especially in colorectal cancer cells 
(Clay et al., 1999; Dionne, Levy, Levesque, & Seidman, 2010; S. J. Lee, Kim, Park, 
Woo, & Kim, 2008; Shimada, Kojima, Yoshiura, Hiraishi, & Terano, 2002; Shin et al., 
2009).  
 The cytotoxic effects of J-series prostaglandins likely resulted in part from 
PPARγ activation. PPARγ is a lipid-activated transcription factor that regulates cell 
proliferation, differentiation and apoptosis (Gupta et al., 2003; Sarraf et al., 1998). It is 
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particularly abundant in the colon mucosa, and exhibits upregulated expression in colonic 
tumours (DuBois et al., 1998; Jain et al., 1998). 15d-PGJ2 is an endogenous agonist for 
PPARγ (Soares et al., 2005). PPARγ activation can suppress tumour progression by 
upregulating the expression of genes that promote apoptosis, and downregulating genes 
that inhibit apoptosis. For example, a study by Shimada et al. (2002) found that PPARγ 
activation by 15d-PGJ2 in CRC cells resulted in upregulated expression of the pro-
apoptotic gene gadd153, and downregulated expression of c-myc – a critical gene whose 
protein product suppresses apoptosis. Furthermore, Chen et al. (2002) found that PPARγ 
activation by 15d-PGJ2 inhibited the expression of two major pro-tumorigenic molecules, 
NFκB and Bcl-2, in HT-29 cells. NFκB and Bcl-2 are normally involved in protecting 
cells against apoptosis; therefore, inhibiting their expression induces apoptosis (Chaves et 
al., 2009; Tsujimoto, 1998).  
 In this study PGJ2 and 15d-PGJ2 induced a greater decrease in cell viability than 
PGD2. This might have resulted from the metabolism of PGD2 into 15d-PGJ2. PGD2 
readily undergoes dehydration to form PGJ2 and then 15d-PGJ2 over time (Fitzpatrick & 
Wynalda, 1983; Shibata et al., 2002). In fact, it has been shown that 80% of PGD2 in 
culture medium is converted into J-series prostaglandins over 24 h (Narumiya & 
Fukushima, 1985). In this study, perhaps PGD2 treatment did not induce cell death via its 
cell-surface DP receptors. Instead, it is likely that a significant amount of PGD2 was 
converted into 15d-PGJ2, which then induced apoptosis via PPARγ activation (Richard, 
Lowthers & Blay, 2007). Furthermore, the rate of PGJ2 conversion to 15d-PGJ2 is likely 
faster than that of PGD2 since it undergoes one less step in the biosynthesis pathway. As 
a result, more 15d-PGJ2 would be produced during PGJ2 metabolism over unit time, 
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producing a greater decrease in cell viability than PGD2. PGF2α had little effect on cell 
viability likely because it is not produced in the J-series prostaglandin biosynthesis 
pathway. 
5.3 Prostaglandins did not significantly upregulate DPPIV/CD26 dipeptidase 
activity after controlling for cell death 
In order to control for cell death, DPPIV/CD26 dipeptidase activity was 
normalized to viable cell number. This method revealed that prostaglandins did not 
significantly upregulate DPPIV enzyme activity on HT-29 cells. There was however a 
much higher mean enzyme activity at high J-series prostaglandin concentrations (which 
did not reach statistical significance as a definite change). Interestingly, these data 
showed substantial variability between experimental replications. The magnitude of 
heightened average DPPIV enzyme activity varied greatly between experiments; some 
showed a dramatic increase in DPPIV activity, while others only showed a slight 
increase. This led me to consider whether the variability in results may have resulted 
from different aspects of cell culture in each experiment. Cell confluency affected the 
magnitude of cell response to prostaglandin treatment. Initial results had suggested that 
15d-PGJ2 had a greater effect on DPPIV activity on 60% confluent cells than on 90% 
confluent cells, although cytotoxicity assays ultimately showed that these results were 
skewed by cell death.  
Increasing cell confluency tends to decrease cell sensitivity to a range of cell 
treatments, shifting the dose-response curve to the right. This has for example been 
shown on HT-29 cells, where increasing cell number resulted in a steady decrease in the 
maximum cell growth response to adenosine treatment (Mujoomdar, Hoskin & Blay, 
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2003). Although the reason for this confluence-dependent decrease in sensitivity is likely 
complex, it may have affected DPPIV enzyme activity data differently in different 
experiments, thereby preventing a statistically significant outcome. 
Although no statistically significant elevation in DPPIV/CD26 dipeptidase 
activity was found, there was a subjective sense that the enzyme activity may still have 
been upregulated. This was because some replicates of the DPPIV enzyme assay revealed 
dramatic increases in dipeptidase activity at high concentrations of PGJ2 and 15d-PGJ2. If 
the J-series prostaglandins did indeed increase DPPIV/CD26 dipeptidase activity, this 
may inactivate the pro-tumorigenic chemokine CXCL12 to a higher degree. As a result, 
CXCL12-mediated tumour cell migration would decrease, which has been shown by a 
previous study on prostate cancer cells (Sun et al., 2008). Furthermore, DPPIV-induced 
inactivation of CXCL12 has also been shown to inhibit CXCL12-mediated endometrial 
cancer cell proliferation (Mizokami et al., 2004). Therefore, upregulated DPPIV 
dipeptidase activity could impede tumour growth and metastasis by further inactivating 
CXCL12. The mechanism by which J-series prostaglandins could have upregulated 
DPPIV/CD26 dipeptidase activity remains to be elucidated.  
5.4 Prostaglandins did not upregulate DPPIV/CD26 expression 
If in fact DPPIV dipeptidase was upregulated by J-series prostaglandins, this 
apparently did not result from a higher abundance of DPPIV/CD26. End-point PCR 
showed no apparent change in DPPIV/CD26 mRNA expression after prostaglandin 
treatment. However, qPCR – a more sensitive technique than end-point PCR – showed a 
significant decrease in DPPIV/CD26 mRNA at high concentrations of 15d-PGJ2. This 
finding contradicted my prediction that 15d-PGJ2 would increase DPPIV/CD26 
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expression. Although the reason behind decreased DPPIV/CD26 mRNA expression is 
unclear, there was no apparent functional significance of decreased DPPIV/CD26 
mRNA, since its whole-cell protein expression remained unchanged after 15d-PGJ2 
treatment.  
The reason for the contradictory results between end-point PCR and qPCR is 
unclear. The same CD26 and GAPDH primers were used in both techniques, a melt curve 
analysis revealed no evidence for the formation of primer dimers, and the amplification 
efficiency of each primer was 1.95 or higher (with 2 being the maximum efficiency). 
Furthermore, negative control samples did not indicate genomic DNA contamination of 
the distilled water used for primer dilution, nor of the RNA samples that were not reverse 
transcribed. Although qPCR is more sensitive to changes in mRNA expression than end-
point PCR (and is thus the most common method for quantifying mRNA expression) the 
technique is still somewhat limited (Bustin, 2002). For instance, mRNA is unstable, and 
therefore the concentration of corresponding cDNA may not be equal to the starting 
concentration of mRNA. Measuring GAPDH expression controls for these potential 
differences in cDNA loading between samples; however, using GAPDH as a 
housekeeping gene may actually be problematic, as its levels have shown to be 
heterogenous in cell subpopulations of the same origin (Goidin et al., 2001).   
Despite these inconsistent changes in DPPIV/CD26 mRNA expression, the 
abundance of whole-cell DPPIV/CD26 protein did not change with 15d-PGJ2 treatment, 
as assessed with Western blotting. It was not particularly unusual that DPPIV/CD26 
protein expression remained constant despite my qPCR findings, since mRNA expression 
does not always predict protein expression (de Sousa Abreu, Penalva, Marcotte, & Vogel, 
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2009). This discrepancy is mostly attributed to processes downstream of transcription, 
such as post transcriptional modifications (Maier, Guell, & Serrano, 2009). Post-
transcriptional modifications control gene expression at the RNA level, and include RNA 
processing (i.e. capping and poly-A tail addition), alternative splicing, and the functions 
of small interfering RNA (siRNA) and microRNA (miRNA) (Zhao, Roundtree, & He, 
2017). RNA processing modifies the primary mRNA transcript to eventually promote its 
expression, whereas alternative splicing results in different proteins being expressed from 
the same gene (Y. Lee & Rio, 2015; Licatalosi & Darnell, 2010). Furthermore, mRNA 
can be degraded by miRNA and siRNA, thereby suppressing protein translation 
(Iwakawa & Tomari, 2015; Y. Zeng, Yi, & Cullen, 2003). There are many complex 
processes that can occur between transcription and translation that may have prevented 
the translation of DPPIV/CD26 mRNA directly after it was downregulated by 15d-PGJ2. 
Prostaglandin treatment also did not change cell-surface DPPIV/CD26 protein 
expression or localization. The high intensity of immunofluorescence remained constant 
at each prostaglandin concentration, as did the cellular pattern. Any increase in DPPIV 
enzyme activity after J-series prostaglandin treatment (which was suggested by some of 
my data but needs to be confirmed for possible statistical significance) would therefore 
not be explained by an increase in DPPIV/CD26 cell-surface protein expression. 
However, this observation did confirm that a substantial amount of DPPIV/CD26 was 
present on the surface of HT-29 cells (Tan, Mujoomdar & Blay, 2004).  
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5.5 15d-PGJ2 may have decreased DPPIV/CD26-mediated cell migration across the 
extracellular matrix 
Thus far, prostaglandin treatment did not appear to significantly upregulate 
DPPIV dipeptidase activity or protein expression. My last experiments explored another 
function of DPPIV/CD26, which is promoting cell adhesion to and migration across the 
ECM (Piazza et al., 1989). A wound-healing assay was performed to measure the rate of 
non-directed cell migration across the ECM. Two scenarios with different cell lines 
mimicked i) general cancer cell migration at the tumour invasive front, and ii) normal cell 
migration during wound healing. The highest concentration of 15d-PGJ2 significantly 
decreased the rate of wound closure by both HT-29 and NIH3T3 cells. However, it is 
unclear whether wound closure was the result of cell migration into the wound, or cell 
proliferation around the wound which resulted in a greater number of cells contributing to 
would closure. NIH3T3 cells appeared to be migrating into the wound due to their 
increased dispersion over time, whereas HT-29 cells exhibited behaviours and 
morphologies indicative of accelerated proliferation and subsequent cell death. The 
accelerated proliferation of HT-29 cells was likely due to the addition of culture medium 
containing 20% FBS intended to stimulate cell migration, but which also contains more 
growth factors than the 10% NCS that the cells were growing in before the assay. It 
therefore seems unlikely that 15d-PGJ2 did in fact increase HT-29 cell migration across 
the ECM, as would be expected if there was a change in functional DPPIV/CD26 protein, 
although the capacity of 15d-PGJ2 to alter cell migration was confirmed by the NIH3T3 
normal fibroblast model. 
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15d-PGJ2 may have decreased cell migration across the ECM via DPPIV-
dependent or DPPIV-independent mechanisms. The potential increase in DPPIV/CD26 
dipeptidase activity may have resulted in an increased inactivation of CXCL12, thereby 
decreasing CXCL12-mediated cell migration. CXCL12-mediated cell migration could 
have also decreased independently of DPPIV/CD26 activity, as 15d-PGJ2 downregulates 
its receptor CXCR4 likely through activating PPARγ and inhibiting NFκB (Richard, 
Lowthers & Blay, 2007). PPARγ activation has also shown to reduce hepatocarcinoma 
cell migration by downregulating the expression of matrix metalloproteinases (MMPs) 
MMP9 and MMP13 (Shen et al., 2012). MMPs facilitate cell migration by degrading 
components of the ECM; MMP9 primarily degrades type IV and V collagen, whereas 
MMP13 degrades type I, II and III collagen (Howes et al., 2014; Z. S. Zeng, Cohen, & 
Guillem, 1999). Degradation of ECM collagen creates cavities through which cells can 
freely move (Howes et al., 2014).  
5.6 15d-PGJ2 treatment degraded at high concentrations in cell culture medium  
 In the different approaches of my project, prostaglandin treatment did not 
significantly upregulate DPPIV expression and activity as hypothesized. The lack of cell 
response might have occurred due to an insufficient amount of bioactive prostaglandins 
available during treatment. After HPLC analysis, 15d-PGJ2 was found to significantly 
degrade in culture medium after 30 min, intriguingly only at the highest concentration. 
Therefore, during treatment, a large portion of the prostaglandin at the normally effective 
concentrations may have degraded before it could affect DPPIV/CD26 expression and 
activity. Eicosanoids are quite unstable and have short half-lives ranging from seconds to 
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minutes, rendering them difficult to study in dose-response relationships (Folco & 
Murphy, 2006; Funk, 2001).  
The instability of prostaglandins in serum-supplemented culture medium may be 
due to the presence of serum albumin. Prostaglandins have been shown to bind to the 
same site of albumin whose microenvironment is significantly alkaline (with a pH equal 
to or greater than 10.0) (Fitzpatrick & Waynalda, 1981). Albumin subsequently catalyzes 
dehydration and isomerization reactions to break down bound prostaglandins (Fitzpatrick 
& Waynalda, 1981). 15d-PGJ2 has shown to bind to bovine serum albumin (BSA) when 
added to cardiomyocytes cultured in 10% fetal calf serum (FCS) (Rajakariar et al., 2007). 
As a result, less than 4% of the initial 15d-PGJ2 treatment was detectable by liquid 
chromatography tandem mass spectrometry after 24 h. Furthermore, prostaglandins 
containing a β-hydroxy ketone have been shown to readily bind to albumin, and this 
greatly reduces their stability (Fitzpatrick & Waynalda, 1981; Fitzpatrick & Wynalda, 
1983). The use of serum-free medium may decrease extracellular breakdown of 
prostaglandins in vitro. In vivo, 15d-PGJ2 can be loaded into solid lipid nanoparticles to 
prevent its degradation (de Melo et al., 2016). 
5.7 Perspectives 
In this study I examined the relationships between three components of the 
colonic tumour microenvironment – prostaglandins, CXCR4 and DPPIV/CD26. Contrary 
to my hypothesis, prostaglandin treatment did not significantly upregulate DPPIV/CD26 
expression and activity on HT-29 cells. However, there were suggestions of increased 
DPPIV/CD26 dipeptidase activity after J-series prostaglandin treatment. Although 
reasons for this possible upregulation are unclear, perhaps it suggests that DPPIV/CD26 
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and CXCR4 are only related through the DPPIV substrate and CXCR4 ligand CXCL12, 
rather than through more complex mechanisms. 
If DPPIV/CD26 and CXCR4 do exhibit a complex relationship, it may involve 
the extracellular signal-regulated kinase (ERK) 1/2 signal- mitogen-activated protein 
kinase (MAPK) pathway. Increased DPPIV/CD26 expression in prostate cancer cells has 
been associated with the inactivation of ERK 1/2 MAP kinase (Wesley, McGroarty, & 
Homoyouni, 2005). Inactivating ERK 1/2 MAP kinase inhibits the transcription factor 
NFκB, which has been shown to promote the expression of CXCR4 in breast cancer cells 
(Helbig et al., 2003). Inhibiting NFκB would thus reduce the expression of CXCR4 on 
the cell-surface. Therefore, increasing DPPIV/CD26 may subsequently decrease CXCR4 
expression via inactivating ERK 1/2 MAP kinase.  
The relationship between DPPIV/CD26 and relationship may be unidirectional. 
Manipulating DPPIV/CD26 may cause the opposite change in CXCR4 expression; 
however, targeting CXCR4 expression might not induce the opposite change in 
DPPIV/CD26. In fact, a study by Miyanishi et al. (2010) found that knocking down 
CXCR4 expression via siRNA actually decreased DPPIV/CD26 protein expression on 
ovarian carcinoma cells. Therefore, DPPIV/CD26 expression and activity may not have 
increased in my own study through targeting CXCR4 via prostaglandin treatment. 
 The possibility remains that DPPIV/CD26 and CXCR4 are not always inversely 
related. Interestingly, the two proteins have been shown to physically associate on the 
membranes of human T-lymphocytes (Herrera et al., 2001). In a study by Herrera et al. 
(2001), DPPIV/CD26 and CXCR4 were shown to colocalize on the cell surface, as 
fluorescent micrographs revealed the physical overlap of their structures. Furthermore, 
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these two proteins coimmunoprecipitated from the plasma membrane, and cointernalized 
upon exposure to CXCL12 (Herrera et al., 2001). Thus, DPPIV/CD26 and CXCR4 may 
either directly associate on the plasma membrane, or associate through a larger protein 
complex (Herrera et al., 2001).  
5.8 Limitations 
 Cancer is a highly heterogeneous disease, and its characteristics substantially 
differ between individual patients. This project primarily focused on one human colon 
carcinoma cell line, HT-29, which originated from a 44-year old Caucasian female 
patient. Even when derived from the same type of tumour, cell lines can differ in 
morphology, degree of differentiation, and DPPIV/CD26 expression as well as other 
traits. Different CRC cell lines may show different responses to prostaglandin treatment. 
Therefore, multiple cell lines derived from colonic tumours should be compared. 
 Tumour-derived cell lines help us understand the mechanisms of cancer, and 
serve as preclinical models for assessing the toxicity and efficacy of novel therapies. 
However, these in vitro studies come with several limitations. First, cell lines can be 
misidentified due to changes in morphology when cultured over time, or cross 
contamination with another cell line. Second, in vitro concentrations of a compound are 
difficult to extrapolate to in vivo doses. The chosen prostaglandin concentrations in this 
project cannot be directly translated into corresponding doses for animal models. Finally, 
we cannot exactly replicate the colonic tumour microenvironment in vitro. Cells will 
inevitably behave differently when isolated from organisms and grown in culture 
medium. 
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 In vitro studies on DPPIV/CD26 are limited by the existence of several DPPIV 
homologues. These homologues exhibit structural and/or functional analogies to DPPIV 
(H. Zhang, Chen, Keane, & Gorrell, 2013). For example, DPP8 and DPP9 exhibit similar 
dipeptidase activity to DPPIV/CD26 in that they also cleave Xaa-Pro polypeptides at the 
penultimate position (C. A. Abbott et al., 2000). Therefore, when intending to exclusively 
measure DPPIV activity through its cleavage of Gly-Pro-pNA, DPP8 and DPP9 might 
interfere with these results by cleaving the same substrate. However, this would only be a 
minor interference, since DPP8 and DPP9 cleave substrates with a weaker catalytic 
efficiency than DPPIV, and are located in the cytoplasm rather than on the cell surface 
(C. A. Abbott et al., 2000; Ajami et al., 2008; Bjelke et al., 2006). Nevertheless, one 
should be wary of the functional and structural similarities between DPPIV and its 
homologues when exclusively studying one of these enzymes.  
Studies on DPPIV/CD26 in colorectal cancer are also limited by the discordant 
literature on its levels of expression and activity. Some studies have reported upregulated 
DPPIV/CD26 expression in CRC, while others have reported a downregulation (Havra et 
al., 2008). Furthermore, despite exerting several anti-metastatic functions, the net effect 
of DPPIV/CD26 on cancer progression varies in the literature (Havre et al., 2008). The 
location of the tumour in the colon may determine the level and significance of DPPIV 
activity (Kate, Vandeningh, Khan & Bosman, 1986; Kate et al., 1985). If so, there are 
likely individual differences in DPPIV/CD26 between CRC patients that ought to be 
considered if DPPIV eventually serves as a prognostic biomarker, or is targeted by a 
novel therapy.  
	   94 
5.9 Future Directions  
  In this project, the unstable prostaglandin 15d-PGJ2 may have degraded in the 
culture medium before it could induce a consistent cell response at high concentrations. 
Further studies would need to confirm whether 15d-PGJ2 treatment is sufficiently 
available to cultured cells to affect DPPIV/CD26 levels. This may include lysing cells 
and measuring intracellular 15d-PGJ2 after treatment by HPLC, and using serum-free 
culture medium to prevent albumin from degrading 15d-PGJ2. If optimal concentrations 
of stable 15d-PGJ2 are established, then the effect of J-series prostaglandins on 
DPPIV/CD26 dipeptidase activity can be further investigated with perhaps less variability 
between results. For instance, the effect of 15d-PGJ2 on CXCL12 degradation by 
DPPIV/CD26 could be investigated, followed by its effect on CXCL12-mediated 
directional CRC cell migration in vitro and in vivo. Furthermore, the directionality of the 
inverse relationship between DPPIV/CD26 and CXCR4 may be further investigated by 
targeting DPPIV/CD26 instead of CXCR4. This can be accomplished by using 
DPPIV/CD26 inhibitors such as diprotin A, or DPPIV/CD26 knockdown via siRNA.  
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